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ABSTRACT
CHARACTERIZATION OF ANGIOTENSIN II
RECEPTOR SUBTYPES IN THE BRAIN
by
David Saylor
The present studies explore binding, distribution, and function of angiotensin II 
(All) receptors (ATi and AT2) in the brain.
The discovery that sulfhydryl reducing agents masked some but not all All 
receptors in the brain prompts an evaluation of commonly used binding assay 
buffer constituents. EDTA enhances binding (40%) at both AT^ and AT2 nuclei, 
while bacitracin did not alter binding at either receptor subtype. Phenanthroline 
and BSA differentially altered binding at A ^  (220% of control) and AT2 (118% of 
control) receptors. The results indicate that phenanthroline and BSA would be 
poor buffer constituents for studies comparing binding at ATi and AT2 receptors.
All receptors were mapped in normotensive and genetically hypertensive 
hamster brains and the subtype composition estimated for a number of brain 
nuclei and the pituitary. Binding in the hamster was similar to that previously 
observed in the rat brain with exceptions: 1) additional binding in the medial 
habenula and interpeduncuiar nuclei, 2) absence of binding in the inferior olive, 
suprachiasmatic nucleus, medial amygdala, piriform cortex, and subthalamic 
nucleus and 3) quantitative differences in the dorsomotor nucleus of the vagus, 
striatum, hippocampus and anterior pituitary. Unlike studies of the normotensive 
and spontaneously hypertensive rat, we found no significant differences in 
binding distribution, density or subtype composition when comparing normal and 
genetically hypertensive hamsters.
Finally, the effects of brain angiotensin II (All) on central catecholamine utilization 
were determined. W e found no significant differences in norepinephrine, 
epinephrine or dopamine utilization in rat brain homogenates following 
intracerebroventricular injection of All. Although there is evidence that All alters 
catecholamine utilization in some brain nuclei, these alterations appear limited 
(anatomically and/or quantitatively) to a relatively small portion of the brain 
catecholaminergic system.
iii
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The results indicate that the selection of buffer constituents is an important 
consideration for All binding studies, that there are minor species differences in 
the distribution of All receptors in the brain and that despite substantial functional 
and anatomical overlap, only a relatively small portion of the brain 
catecholaminergic system is modulated by angiotensin II.
iv
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CHAPTER 1 
INTRODUCTION
The Renin Angiotensin System 
Nearly a century ago, Tigerstedt and Bergman (1898) obtained an extract 
from the renal cortex of rabbits that produced a pressor response upon 
intravenous injection. They named this substance ‘renin’ and characterized it as 
heat sensitive and impermeable to semi-permeable membranes, indicating that 
the substance was most likely (as was later confirmed) a protein. Furthermore, 
Tigerstedt thought the substance was probably released from the kidney into the 
circulation to produce its effects (this has also been confirmed).
Later, Goldblatt, a pathologist, noticed arterio- and arteriolosclerosis in 
hypertensive patients at autopsy. Goldblatt suspected that obstruction of blood 
flow to the kidney was related to hypertension. In 1934, Goldblatt etal. 
demonstrated sustained hypertension with renal ischemia using constricting 
clamps on the renal arteries of experimental animals. This and additional work by 
Goldblatt proved that this type of hypertension was produced by a humoral agent 
of renal origin (Goldblatt, 1947; 1948). The subsequent search for the humoral 
agent led to the re-discovery of renin.
1
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2Later work revealed that renin did not act alone. Page etal. (1940) and 
Braun-Menendez etal. (1940) independently proposed that renin might act as an 
enzyme and named the substrate angiotonin and hypertensin, respectively. 
Finally, in 1961, Page and Braun-Mendez agreed to call the new substance 
“angiotensin". An early assay for angiotensin in arterial blood samples 
demonstrated that this substance was elevated by a factor of about 20 in 
malignant hypertensive patients, while only about one-half of the patients with 
benign essential hypertension had elevated levels (Kahn etal., 1952). This 
finding stimulated further study of renin and angiotensin. Attempts at purifying 
angiotensin from plasma uncovered two forms - angiotensin I (Al) and 
angiotensin II (All), and another enzyme - angiotensin converting enzyme (ACE) 
that converted one form into the other (Skeggs et al., 1954; Lentz et al., 1956). 
These components collectively form the renin-angiotensin system (RAS) 
(depicted in figure 1-1) with All being the primary affecter molecule. All acts on
Angiotensinogen
Renin
Angiotensin I t
(Decapeptide)
Angiotensin li
(Octapeptide)
Figure 1-1. The renin-angiotensin system.
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3many tissues to produce a variety of effects. Most of the known actions of All 
involve blood pressure regulation, sodium/fluid balance, or growth and 
development. Consistent with the array of actions of this peptide, a number of 
angiotensin receptor subtypes have been described and localized in a number of 
tissues. The profound effect All has on blood pressure has made this system a 
primary target for antihypertensive agents, and a wide variety of drugs is 
currently available to block renin secretion, renin action, conversion from Al to 
All, and All receptors. Each component of this diverse and complex system will 
now be discussed individually.
Renin
Preprorenin (45 kD) is produced in the kidney. The human cDNA has 
been cloned and sequenced (Parmentier etal., 1982). This precursor is 
processed post-translationally into the still inactive prorenin, then finally, into the 
active renin. The final processing of prorenin can occur intracellularly, or in the 
circulation following secretion (plasma prorenin levels are approximately 10'11 M). 
Renin is secreted in two forms. A two chain form is secreted by a regulated 
mechanism while a single chain renin (with 6 times the enzymatic activity) is 
constitutively secreted (Pratt etal., 1983). Interestingly, circulating renin is 
apparently complexed to a renin-binding protein that inhibits its action (Inone et 
al., 1990). Renin is very specific in function and substrate and does not appear to 
belong to any general class of proteases. However, there are some structural
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4similarities to the acid proteases pepsin and cathepsin D, which are also capable 
of producing angiotensin I (Paiva and Grandino, 1973; Hackenthal etal., 1978).
The renin catalyzed conversion of angiotensinogen to Al is the 
physiologically regulated reaction of the RAS with plasma All levels determined 
by plasma renin activity. Release of renin is regulated by a host of factors of both 
intra and extrarenal origin. Within the kidney, the renal arterial perfusion pressure 
and sodium delivery to the macula densa regulate renin release. Additional 
regulatory components include the renal nerves, circulating catecholamines, All, 
and vasopressin. Additional stimuli, both endogenous and exogenous to the 
kidney, may override other factors under certain conditions. Renin release may 
be reflexively altered by carotid sinus arterial baroreceptors and/or by vagally 
mediated cardiopulmonary receptors. Additionally, psychological stresses are 
known to increase renin release. All of these factors are integrated by 
juxtaglomerular cells by a not completely understood process that probably 
involves a common second messenger system (Zehr etal., 1980; Katz and 
Malvin, 1993). Products of the arachidonic acid and cyclooxygenase interaction 
and/or prostaglandins may be involved (Katz and Malvin, 1993).
Angiotensinogen
Angiotensinogen, a 55-60kD glycoprotein produced and constitutively 
secreted (Deschepper and Reudelhuber, 1990) by the liver, has been isolated 
and characterized. Furthermore, cDNA cloning and analysis have provided the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5primary structures of rat (Ohkubo etal., 1983), human (Kageyama etal., 1984), 
and mouse (Clouston etal., 1988) angiotensinogen. This tetradecapeptide differs 
at the N-terminus in different species (Tewksbury etal., 1981), allowing 
polyclonal and monoclonal antibody production and direct immunoassay of the 
C-terminal portion (Genain etal., 1984).
Angiotensinogen is present in plasma at about 1 |iM and in cerebrospinal 
fluid (CSF) (Genain etal., 1984; Ito etal., 1980; Schelling etal., 1983). Since the 
Km of renin for angiotensinogen is around 1.25 jiM, angiotensinogen is not in vast 
excess and alterations in plasma angiotensinogen levels can alter plasma All 
levels. However, because changes in plasma angiotensinogen levels occur 
slowly (hours or days) this substance does not mediate acute All responses. 
Angiotensinogen release is regulated by angiotensin II, glucocorticoids 
(especially dexamethasone), estrogens and thyroid hormones (Tewksbury, 1983; 
Menard etal., 1983). It is important to note that angiotensin II is a positive 
regulator for angiotensinogen (Li and Brasier, 1996), but negatively regulates 
renin (Menard etal., 1983; Hermann and Dzau, 1983). Thus, angiotensin II 
inhibits further angiotensin II formation and causes a replenishment of the used 
angiotensinogen.
Interestingly, angiotensinogen levels are increased with inflammation 
(Nielsen and Knudsen, 1987). All is also elevated and may participate in the 
immune response during inflammation (Femandez-Castello eta l., 1987).
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6Angiotensin Converting Enzyme
Skeggs and co-workers (1956) discovered angiotensin converting enzyme 
(ACE) while attempting to isolate angiotensin I. In the presence of chlorine a 
‘second form’ of angiotensin (missing two amino acids from the C-terminal) was 
isolated. Independently, in the early 1960s, kininase II, which cleaves a dipeptide 
from bradykinin, was discovered by Yang and Erdos (1967). Yang and co­
workers later demonstrated that both reactions were mediated by a single 
dipeptidyl decarboxypeptidase (1970). This single enzyme, therefore, inactivates 
a hypotensive agent and activates a pressor agent. This enzyme also cleaves 
des-Arg9-bradykinin, neurotensin, chemotactic peptide, substance P, luteinizing 
hormone releasing hormone, cholecysiokinin-8, [Leu15]gastrinn-17 and the opioid 
peptides enkephalin, heptapeptide, p-neo-endorphin, and dynorphini-a.
ACE exists in bound and free forms. A membrane-bound form is present 
in vascular beds, bound to endothelial cells. The lung, having a large vascular 
bed, hosts much of the ACE activity for cleaving circulating peptides including Al 
and bradykinin. However, membrane bound ACE is also present in arteries and 
veins (endothelial), microvilli, kidney proximal tubules, brush border of placenta, 
intestine and choroid plexus (epithelial), subfornical organ, pallidonigral dendrites 
and median eminence (neuroepithelial), testis, prostrate and epididymis (male 
genital tract). Free ACE is present in blood, urine, lung edema, amniotic fluid, 
cerebrospinal fluid, lymph, and seminal plasma. It is not known if the free form is
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7secreted or cleaved from the membrane bound C-terminal fragment (Skidgel and 
Erdos, 1993).
The involvement of this enzyme in the RAS is in the formation of All from 
Al. The cleavage of Al has a Km of approximately 5x1 O'5 M. Since Al is present in 
sub nanomolar concentrations, the rate of reaction is proportional to Al 
concentration, which is renin dependent. Therefore, this step is not 
physiologically regulatory. However, the metal requiring nature of this enzyme 
makes it a primary target for intervention. ACE inhibitors form a large and 
clinically important class of antihypertensive agents.
Angiotensins
Angiotensin I (Al) (figure 1-2) is formed by the action of renin on 
angiotensinogen. This decapeptide serves as substrate for angiotensin
Angiotensin Peptides
A l  (^ s ^ !(^ ^ ^ (V a l)(^ ^ T )(^ n e ^ X H is )(P ro )(^ h ^ H is )(L e u ^ i
All
AIII 
AIV 
A( 1-7)
Figure 1-2.  Amino acid sequences of angiotensin peptides.
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8converting enzyme which removes two amino acids from the C-terminal end to 
produce the active octapeptide angiotensin II (All).
All is now known to affect multiple targets to produce a co-ordinated 
cardiovascular response. All increases heart rate and contractile force, constricts 
blood vessel smooth muscle cells, and stimulates the pituitary to secrete 
vasopressin, another potent vasoconstrictor (Skeggs, Kahn, and Shumway,
1956). All also regulates sodium and fluid balance by stimulating aldosterone 
release from glomerulosa cells of the adrenal cortex (Davis, 1963; Wright and 
Harding, 1994). All acts in the kidney to decrease filtration by contracting 
glomerular mesangial cells (Fujiwara etal., 1989) and smooth muscle cells in 
efferent arterioles (Gassee et al., 1976; Gekle and Silbernagl, 1993) and 
excretion by increasing sodium and water re-absorption in the proximal tubule 
(Mitchell and Navar, 1991). All stimulates catecholamine release in the brain 
(Jenkins etal., 1995), and from the adrenal chromaffin cells (Kimura etal., 1992). 
Finally, All acts in the brain to stimulate drinking and sodium appetite as well as 
increases sympathetic tone and decreases parasympathetic tone (Wright and 
Harding, 1992). All has also been implicated in reproduction (Morris & Paulson, 
1994; Phillips etal., 1995), growth and development (Huckle and Earp, 1994; 
Wolf, 1995), inflammation (Farber etal., 1990; Weinstock etal., 1987), right 
ventricular hypertrophy in hypertension (Waeberand Bruner, 1996), and 
cognition and memory (Wright and Harding, 1994).
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9Early attempts to antagonize All activity were limited to the disadvantages 
of peptidic substitution based antagonists. Often a sarcosine substitution at 
position 1 was employed to increase stability. Further substitution at position 8 
removes activity and may further stabilize the antagonist. More recently, non- 
peptidic receptor antagonists have been developed and demonstrate 
heterogeneity in receptor types (Chiu etal., 1989; Whitebread etal., 1989).
Angiotensin III (Alll) can be produced by aminopeptidase activity on All, or 
from Al without All production via aminopeptidase activity and subsequent ACE 
action. This peptide retains about 30%  of the pressor activity of All (Khosla et al., 
1974). However, Alll might play a more significant role in mediating aldosterone 
release (Campbell etal., 1974; Mendelsohn and Kachel, 1980) and may be 
equipotent or more potent than All in eliciting vasopressin release from the 
pituitary (Wright and Harding, 1994). Indeed, in the brain, some of the actions 
currently ascribed to All may actually be mediated by Alll or other smaller 
peptide fragments formed locally within the tissue (Papouchado etal., 1995; 
Unger et al., 1988). In fact, Alll is equipotent or more potent than All in activating 
the mas oncogene product. This receptor is structurally similar to angiotensin II 
receptors but is not antagonized by either selective antagonist. Furthermore this 
gene product is expressed in specific brain regions but is expressed in very low 
levels if at all at peripheral sites (Hanley, 1991).
Angiotensin IV (AIV) (amino acids 3-8 of angiotensin II) binds with high 
affinity to a unique receptor type but not to other angiotensin receptors.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Conversely, other angiotensins have very low affinities for the AIV receptor. AIV 
and AIV receptors have been localized to discrete brain regions and to a variety 
of other tissues (Swanson etai., 1992).
Angiotensin-(1-7) (amino acids 1-7 of angiotensin II) also demonstrates 
activity. Schiavone e ta i  (1988) indicate that this fragment is equipotent with All 
in stimulating vasopressin release. In the brain angiotensin-(1-7) mimics some 
but not all All actions (Campagnole-Santos etai., 1990) and appears to be more 
potent that All in stimulating prostaglandin synthesis in glioma cells (Jaiswal et 
al., 1991). However, it is unlikely that this fragment acts via All receptors (Rowe 
etai., 1995).
Angiotensin peptides are degraded through a variety of non-specific 
amino, carboxy, and endopeptidases. Additional fragmentation products are 
thought to be inactive.
Angiotensin Receptors
The search for non-peptidic receptor antagonists led to the discovery of 
angiotensin II receptor subtypes in 1989. The antagonist losartan demonstrates 
selectivity for the A ^  receptor while PD123177 demonstrates AT2  selectivity 
(Chiu etai., 1989; Whitebread etai., 1989). These receptor subtypes are also 
differentially sensitive to sulhydryl reducing agents. All receptors have been 
localized and characterized in a variety of tissues including vascular smooth 
muscle, adrenal cortex, kidney, myocardium, brain, adrenal medulla, liver, uterus,
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pituitary, gut, and gonads (Catt, 1993). The known actions of All are mediated by 
the ATi receptor and are antagonized by losartan but not by PD123177.
Both ATi and AT2  receptors have now been cloned and sequenced 
(Murphy etai., 1991; Sasaki etai., 1991; Nahmias and Strosberg, 1995). A ^  
receptors have been subdivided into AT1a and A T ^  receptors based on 
sequence heterogeneity. However, there appears to be little if any functional 
difference between the ATi types. All three receptor types contain 7 membrane 
spanning regions and meet the structural requirements for G-protein linkage. ATi 
receptor are known to act through the G-proteins Gq and Gj and couple to 
phospholipases C, D2, and A2l adenylate cyclase, and calcium channels (Catt,
1993). Down regulation by All appears to be the most significant factor regulating 
A ^  expression (Lassegue etai., 1994). There is some evidence that AT2 
receptors link to Gj proteins to modulate K+ channels in primary neuronal cultures 
and AT2 expression may be regulated by growth-related factors (Kang etai.,
1994).
Evidence suggests further heterogeneity in both ATi and AT2 receptors. 
Initially, AT2 receptors were thought to be not coupled to guanidine nucleotides 
because of observed insensitivities to GTPyS (Nahnias and Strosberg, 1995). 
Furthermore, some, but perhaps not all, AT2 receptors demonstrate enhanced 
binding in the presence of sulfhydryl reducing agents. There is also some
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evidence for a unique ATi receptor in renal mesangial cells but cloning and 
sequencing will be necessary for confirmation (Lassegue e ta i ,  1994).
Multiple Local Tissue RAS 
There may actually be several independent renin angiotensin systems 
operating locally within certain organs. Various components of the RAS have 
been described in the brain, anterior pituitary, testes, ovaries, adrenal cortex, 
kidneys, heart, blood vessel walls, and brown and white fat (Ganong, 1994). 
However, many of these localizations employ very sensitive molecular methods 
and use polymerase chain reaction (PCR) amplification (Dostal e ta i,  1992; 
Ganong, 1994). The degree of expression may not be physiologically significant 
and could, in some cases, represent incomplete inhibition. All (and/or another 
active angiotensin fragment) probably has paracrine and/or autocrine functions in 
at least some of these tissues and probably acts as a neurotransmitter in the 
brain (Ganong, 1994). These functions may or may not interact with the 
hormonal RAS. However, there is some evidence that plasma renin activity alone 
may not account completely for plasma All levels, suggesting a contribution by at 
least some local systems (Unger e ta i,  1991).
The RAS in the Brain 
The evidence for an independent local angiotensin system is most 
compelling in the brain. Sulfhydryl reducing agents such as dithiothreitol and 
mercaptoethanol have been found to differentially affect binding with respect to
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angiotensin II receptor subtypes in the brain (Rowe etai. 1990a; Speth etai.,
1990). Significantly, a number of previously unreported binding sites were 
observed (Rowe et a i, 1990b) in the absence of sulfhydryl reducing agents, 
which were routinely included in angiotensin II binding assays in the brain prior to 
this discovery. Interestingly, many brain nuclei demonstrating binding are not 
known to be involved in cardiovascular or dipsogenic activity, suggesting that 
angiotensin II may have additional functionality in the brain. Additionally, most of 
the angiotensin II receptor populations in the brain are not accessible from the 
circumventricular organs, suggesting that a source of angiotensin II exists within 
the brain.
All of the components of the renin angiotensin system have now been 
localized in the brain (Moffet etai., 1987; Phillips etai., 1993). Angiotensinogen, 
angiotensin II, and angiotensin II receptors have been localized within the brain 
by in situmRNA hybridization (Fuxe etai., 1988), immunocytochemistry (Lind et 
a i, 1985), and receptor autoradiography (Gehlert e ta i,  1986; Mendelsohn e ta i,
1984) respectively, and demonstrate good anatomical correspondence in many 
brain areas (Bunnemann e ta i,  1991).
Despite generally low levels in the brain, renin has been localized in 
neurons and nerve terminals and may also be present in glial cells (Fuxe et a i, 
1980; Fischer-Ferraro e ta i,  1971; Samani e ta i,  1988; Yang and Neff, 1972). 
Most of the angiotensin converting enzyme in the brain is located in the choroid 
plexus and circumventricular organs with some on neuronal membranes
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(Ganong, 1993). However, there are other enzymes present in the brain (like 
tonin and cathepsin G) that are capable of generating angiotensin II from 
angiotensin I or directly from angiotensinogen (Boucher e ta i,  1974; Tonnesen 
etai. 1982).
Angiotensinogen messenger RNA (mRNA) has been localized to 
astrocytes, while angiotensinogen immunoreactivity has also been found in 
neurons. This suggests that angiotensinogen is produced only in astrocytes but 
is then taken up by neurons for conversion to angiotensin II. Angiotensinogen 
(mRNA and/or immunoreactivity), angiotensin II, and angiotensin II receptors 
have been localized to the subfornical organ, area postrema, median eminence, 
spinal trigeminal nucleus, inferior olivary nucleus, dorsal motor nucleus of the 
vagus, nucleus tractus solitarius, locus coeruleus, regions of the central grey, 
ventral nuclear complex, reuniens nucleus, mammillary nucleus, ventromedial 
and dorsomedial nuclei, suprachiasmatic nucleus, paraventricular and 
periventricular nuclei, supraoptic nucleus, medial preoptic area, median preoptic 
nucleus, and lateral septum.
However, angiotensinogen and angiotensin II are found in a few areas 
where angiotensin II receptors have not been reported. These areas include 
pontine central grey, the substantia nigra, the zona incerta, thalamic 
paraventricular nucleus, arcuate nucleus, the lateral preoptic area, medial septal 
nucleus, nuclei of the band of Broca, bed nucleus of the stria terminalis, and the 
central amygdaloid nucleus (Bunneman etai., 1991).
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Summary and Discussion 
The kidney was linked to cardiovascular function in classical experiments 
by Tigerstedt and Bergman (1898). Additional work revealed a hormone system 
involving angiotensinogen from the liver, renin from the kidney and a converting 
enzyme from endothelial cells. The primary affector peptide, angiotensin II, acts 
on receptors present in a number of peripheral tissues and the brain to co­
ordinate complex cardiovascular and fluid/salt balance responses.
Recent discoveries indicate that the renin-angiotensin system may also 
have paracrine/autocrine functions. Evidence is mounting for the existence of 
local RAS within a variety of tissues/organ systems. The most convincing 
evidence exists in the brain, where angiotensin II appears to act as a 
neurotransmitter. All of the components of the RAS have been found in the brain 
as well as alternative synthesis pathways capable of forming angiotensin II.
Despite the generally good co-localization of components of the renin 
angiotensin system within the brain, a few mismatches remain. Bunnemann et 
ai. (1991) describe three major types of mismatches occurring in the brain renin 
angiotensin system: 1 ) The presence of angiotensinogen mRNA, 
angiotensinogen immunoreactivity, All receptors, and the lack of angiotensin 
converting enzyme and/or All in distinct areas; 2) Angiotensinogen mRNA and 
immunoreactivity in association with moderate to low levels of converting
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enzyme, but All and All receptors are not detectable and 3) The lack of 
detectable binding sites for All with the presence of all the other components of 
the RAS. The first discrepancy may be due to a relatively short half life of 
angiotensin II making detection of low levels difficult. With respect to the second 
type of discrepancy, angiotensinogen mRNA appears only in astrocytes 
(Bunnemann etai., 1992; Stornetta etai.,  1988) whiie angiotensinogen-like 
immunoreactivity has also been visualized in some neurons (Intebi etai., 1990; 
Thomas and Semia, 1988). Angiotensinogen may be produced by astrocytes and 
taken up by neurons at the location of the cell body, packages, transported, and 
converted to angiotensin II in transport or in the distant nerve terminal. Therefore, 
we might expect angiotensin II and angiotensin II receptors to be localized 
differently than angiotensinogen mRNA and immunoreactivity. Concerning the 
second type of discrepancy, the co-localization of all necessary components of 
the RAS with the exception of angiotensin II receptors, angiotensin II could be 
formed in (and present at) cell bodies as well as transported to nerve terminals at 
distant sites where All receptors would be localized. However, the possibility 
remains that some angiotensin II receptors evade detection in current assays.
The remaining discrepancies with respect to the absence of All receptors where 
additional RAS components are present may be indicative of additional 
angiotensin II receptor subtypes being masked by in vitro conditions. Previously, 
the discovery of angiotensin II receptor subtypes and the subsequent unmasking 
of additional All binding in the brain resolved some discrepancies in distributions
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
17
of RAS components in the brain (Rowe etai., 1990b). Further evidence of 
additional receptor subtypes comes from recent molecular biology based 
experiments that examine angiotensin receptor genes for sequence and 
processing heterogeneity.
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CHAPTER 2 
SPECIFIC AIMS
The overall objective of the current research is to further characterize AT, 
and AT2 receptors in the central nervous system. Approaches employed to meet 
this objective include: 1 ) verification of buffer medium for binding assays; 2 ) 
evaluation of central AT, and AT2  receptor distributions in the hamster; and 3) 
characterization of the interaction between central angiotensinergic and 
catecholaminergic systems. Each of these experiments is described below.
Evaluation of Buffer Constituents 
Early binding studies examining angiotensin II receptors employed a 
variety of peptidase inhibitors in the binding assay in order to preserve the 
labeled angiotensin II ligand. Indeed, early studies indicated that sulfhydryl 
reducing agents were necessary (Chen etai., 1982; Printz etai., 1987) to protect 
125l-angiotensin II. This practice presupposes that the buffer constituents do not 
affect the binding reaction. However, when amino and carboxy substituted 
angiotensin analogues (i.e. 125l-[Sar1, llea]-Angiotensin II), which are less 
susceptible to aminopeptidase and carboxypeptidase activity, were employed in 
the absence of sulfhydryl reducing agents, additional angiotensin II binding was 
unmasked (Rowe etai., 1990b). Additionally, the differential sensitivity to
18
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sulfhydryl reducing agents corresponds to different angiotensin II receptor 
subtypes (Rowe etai., 1990a). This precedent prompts re-evaluation of 
commonly used buffer constituents to determine if the procedures used provide a 
valid comparison of ATi and AT2  binding characteristics.
Angiotensin II receptor density is measured by in vitro receptor 
autoradiography at a number of brain nuclei known to contain nearly pure 
populations of ATi or AT2 receptors. Receptors are labeled with 1 2 5 I-SIAII in the 
presence and absence of various commonly used buffer constituents to 
determine if an inhibitor preferentially interferes with binding at one or the other 
subtype.
Receptor Localization and Subtype Characterization in the Hamster
The ATi and AT2 receptor distributions are determined in normal and 
genetically hypertensive hamster strains. The brain angiotensin system has been 
implicated in the hypertension of the spontaneously hypertensive rat, which 
demonstrates increased levels of both angiotensin II and angiotensin II receptors 
(Weyhenmeyerand Phillips, 1982; Gehlert etai., 1986b; Hwang etai., 1986). In 
order to determine if this is true of other mammalian species and to attempt to 
correlate angiotensin II receptors in the brain with additional physiological 
systems, angiotensin II receptor subtypes will be examined in the brains of 
normotensive and spontaneously hypertensive hamsters by in vitro receptor 
autoradiography.
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The Effects of Angiotensin II on Brain Catecholamine Utilization
Catecholamines have been implicated in a number of central angiotensin 
II responses (Fitzsimons and Setler, 1975; Reader e ta i ,  1986; Braszko and 
Wisniewski, 1990). Additionally, intracerebroventricular (i.c.v.) injection of 
norepinephrine or dopamine mimics some of the actions of i.c.v. injection of 
angiotensin II. Furthermore, angiotensin II (i.c.v. or microinjection via 
microdialysis) has been shown to alter catecholamine utilization in specific brain 
regions (Sumners and Phillips, 1983; Dwoskin etai., 1992; Jenkins etai., 1995).
Additional evidence suggests that angiotensin II may act as a 
neuromodulator via AT2 receptors in the locus coeruleus (Xiong and Marshall, 
1990,1994). Specifically, angiotensin II inhibited the excitatory stimulation of 
glutamate in a specific manner and was sensitive to AT2, but not A ^  selective 
antagonists. Therefore, we hypothesize that angiotensin II may act, in part, by 
altering catecholamine utilization throughout the central catecholaminergic 
system.
To test this hypothesis, groups of 10 conscious, chronically canulated rats 
will receive i.c.v. injections of All, artificial CSF (aCSF), All + losartan or All + 
PD123177. After decapitation, the brains will be dissected, homogenized, and 
assayed for catecholamine utilization by high performance liquid chromatography 
(HPLC).
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CHAPTER 3 
MATERIALS AND METHODS
In Vitro Receptor Autoradiography 
Animals were anesthetized with Nembutal (80 mg/kg), perfused 
intracardially with chilled phosphate buffered saline, and the brains were 
removed quickly and stored at -20 °C. Whole brains were cryostat sectioned 
(20 pm, -15 °C) and thaw mounted onto sets of adjacent gelatin coated slides. In 
some instances, one slide from each set was thionin stained to serve as a 
histological reference and the other slides were returned to the freezer. Frozen 
slides were placed on a warming plate, pre-incubated in buffer at room 
temperature for 30 minutes, and transferred to buffer containing 1 2 5 l-[sar1 ,ile8]-AII 
(125I-SIAII) for one or two hours. The tissues were then rinsed, dried in a stream 
of hot air, mounted onto boards along with 2 0  pm thick 125l standards 
(Microscales, Amersham, Arlington Heights, IL) and apposed to film (Kodak SB5) 
for 5-6 days. The film was developed with Kodak D-19 developer and 12 5 I-SIAII 
binding was quantified densitometrically using the MCID video based image 
analysis system (Imaging Research Systems, Ontario Canada). Binding was 
determined as fmoles ligand per gram wet weight of brain tissue and specific
21
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binding was calculated as total 12 5 I-SIAII binding minus binding in the presence of 
All (10'6 M).
Thionin Staining
At room temperature, slides containing freshly sectioned tissue were 
incubated sequentially in thionin staining solution (10 min), water ( 2 dips), 50% 
ethanol (2 dips), 70% ethanol (15 seconds), 95% ethanol (1 minute), 100% 
ethanol (3 minutes), and xylene (5 minutes). Finally, coverslips were mounted 
over the slides.
Development of Autoradiograms 
Exposed film (Kodak SB5) was removed from tissue containing cassettes 
in the dark using a photographic safe light. Film was developed with agitation for 
2 minutes in Kodak D-19 Developer, soaked (30 seconds) in a stop solution (2% 
acetic acid) and fixed in Kodak Rapid Fixer (5 minutes). The film was rinsed in 
flowing water for 2 0  minutes or until clear and dipped in photoflo before hanging 
to dry.
Densitometric Image Analysis 
Radioligand binding density was quantitated using an MCID video based 
image analysis system. The camera, light source, and lens were adjusted as 
desired. The lens aperture was then adjusted to provide a green field to define 
the shading error adjustment. The image analysis system was then calibrated for
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linear distance using a reticule. The lens aperture was then adjusted as desired 
and a density calibration was performed using the image of the 125l standards on 
the autoradiogram to be quantitated.
A 0.15 x 0.15 cm2  sampling box was used to quantitate the highest 
observed density (pseudocolor mode) within a given nucleus on an image 
corresponding to an individual brain section. For each treatment group, each 
brain nucleus for each animal was measured on a number of sections (the exact 
number depending upon the anatomical dimension of the nucleus) and an 
average taken. When appropriate measurements for a given nucleus were 
obtained from both the left and the right sides of the brain.
Analysis of Radioligand Degradation 
For each animal, samples were taken from each buffer before and after 60 
or 1 2 0  minute incubation of brain slices. Samples were frozen and shipped with 
dry ice in radioactive packaging to Dr. Robert Speth at Washington State 
University where they were analyzed for 125 I-SIAII and radiolabelled fragments by 
reverse phase Ci8 (microsorb) HPLC (Rainen Instr., Woburn, MA) with a 
radioisotope detector (Beckman Model 171, Beckman Instr., Palo Alto). Peak 
areas for 125l labeled compounds were quantitated as height times width at half 
the peak height. Several peaks were resolved with 19% acetonitrile, 81%  
triethylamine phosphate (TEAP) at pH 3.0. The peak corresponding to 125I-SIAII 
could not be further resolved by extending retention times by using a mobile
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phase with 17% acetonitrile (pH 4.0) or by replacing TEAP with triethylamine 
acetate (TEAA).
Intracerebroventricular Injections 
Animals were anesthetized with nembutal (70 mg/kg, intraperitoneal) and 
surgical anesthesia was maintained with ketamine/acepromasine (intramuscular). 
After trimming the top of the head, animals were placed in a stereotaxic frame. 
Under sterile conditions, a midline incision was made over the scalp and the skin 
deflected. The skull was scraped to remove membranous tissue and positioned 
such that the top of the skull was horizontal and flat. Stereotaxic co-ordinates 
were taken with a drill placed on the bregma surface feature and the drill co­
ordinates were determined to be 0.9 mm posterior and 1 . 6  mm lateral to bregma 
on the left side of the animal. Holes were drilled at this site and approximately 1.5 
mm anteriorly and posteriorly. Screws were placed in the anterior and posterior 
holes. The drill was replaced with the cannula holder and a sterile guide cannula 
was placed within the holder. The cannula tip was placed on bregma and the co­
ordinates taken. The cannula was placed at co-ordinates 0.9 mm posterior, 1 . 6  
mm lateral (left side), and 3.0 mm ventral to bregma. The skull was checked for 
dryness and any fluid on the skull surface was removed. Cranioplastic cement 
(liquid and powder portions) was mixed and applied, under the screw tops, 
covering the screws, around the cannula and into the lower threads on the 
cannula base. After the cement had hardened (about 20 minutes), the cannula
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was released from the holder, the skin was closed around the cannula with 
autoclips and a dummy cannula was screwed into place inside the guide 
cannula.
Approximately 1 week following surgery, cannula placement was 
confirmed by observation of a drinking response following i.c.v. injection of 
angiotensin II (150 picomoles in 3 pi). A syringe (Hamilton, 10 p!) was attached 
via fluid filled tubing to an internal cannula designed to snap into place within the 
guide cannula. The internal cannula was back loaded with 5x10 ‘ 5 M angiotensin 
II in artificial cerebrospinal fluid (aCSF) solution. The dummy cannula was 
replaced with the loaded internal cannula and a 3 pi injection was made. After 
approximately 2 0  seconds, the internal cannula was removed and the dummy 
cannula replaced. The animal was returned to the cage. The water bottle was 
weighed before and approximately 30 minutes following i.c.v. injection. Both time 
until onset of drinking and volume drank were assessed. Passing responses 
began drinking within 3 minutes of injection and drank >12 ml within 30 minutes 
of injection. Often animals failing the initial test passed on successive tests. 
Animals repeatedly failing drink tests (5) or considered to be in poor health were 
excluded from the study.
At least 24 hours following a successful drink test animals were placed 
into 1 of 5 experimental groups. Animals were pre-treated with a catecholamine 
synthesis inhibitor (°c-methyltyrosine, 200 mg/kg IP) or saline solution at 90
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minutes prior to decapitation. Approximately 50 minutes prior to decapitation, 
internal cannula attached to syringes (Hamilton, 10 pi) and preloaded with 1 of 4 
test solutions were placed within the guide cannula as described above. Bolus 
injections of 3 (il were delivered at 45, 30, and 15 minutes prior to decapitation 
and drinking responses were monitored. Decapitation was accomplished with a 
small animal guillotine. Immediately following decapitation, the brain was 
removed and dissected into the left cortex, right cortex, hindbrain and midbrain, 
forebrain, and cerebellum. Each brain region was weighed and homogenized in 3 
ml of homogenizing solution. Following homogenization, an additional 3 ml of 
homogenizing solution was added. Tissue samples were then stored at -70°C 
until catecholamines were extracted.
Catecholamine Extraction from Brain Homoqenates 
Frozen tissue samples were thawed to room temperature and centrifuged 
for 25 minutes at 20,000xg (14000 rpm, Beckman J2-21 centrifuge with pre­
cooled J20.1 rotor, set=2°C). Following centrifugation, the supernatant from each 
sample was collected and stored at -70°C until extraction. Catecholamines were 
extracted from tissue samples by differential affinity to acid washed alumina 
oxide (AAO). Samples (1ml) were placed into vials containing 1 ml Tris buffer and 
50mg AAO and the vials were vortexed and shaken for 1 0 minutes. The liquid 
was removed with a Pasteur pipette and the AAO washed twice with deionized 
water. With the 3rd wash, the AAO is transferred into a microfiltration apparatus
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and centrifuged (Damon IEC HN-SII model, 3500rpm, 8  minutes) to dryness. 
Trichloroacetic acid (200 pi) was added to the AAO and vortexed gently. After 10 
minutes, the trichloroacetic acid was collected by centrifugal filtration as before 
and stored at -70°C until HPLC quantitation.
HPLC Quantitation of Catecholamines 
HPLC quantitation of catecholamines was by electrochemical detection. 
Mobile phase was circulated in a closed circuit from a reservoir, through a pump, 
injection port, guard column, analytical column, detector flow cell, and returned to 
the reservoir. A light helium sparge was maintained through the reservoir to keep 
the mobile phase degassed. The electrochemical detector applied a voltage 
potential of +70 mV across the mobile phase, causing reduction and oxidation of 
active analytes within the mobile phase. After sufficient time, the mobile phase 
equilibrated to the applied voltage and freshly introduced analytes oxidized and 
reduced above the equilibrium redox rate. Samples were introduced into the flow 
at the injector port. The redox current was detected, amplified, and recorded. 
HPLC separation of analytes produced gaussian peaks of redox activity on a 
current/time plot (chart recorder) with specific retention times for each analyte 
separated.
Catecholamine standards were used to tune mobile phase characteristics 
for optimum separation and to asses response factors (observed area under 
peak per amount of analyte in sample) for each catecholamine of interest and for
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the internal standard. Similarly, standards were extracted to asses the extraction 
efficiency (percent of initial catecholamine present in final extract) for each 
catecholamine of interest and for the internal standard. Standards were extracted 
in buffers of varying pH levels to optimize pH of extraction.
Catecholamine extracts from rat brain tissue homogenates were injected 
and the peaks corresponding to NE, EPI, DA, and DHBA analyzed. NE, EPI, and 
DA were measured by adjusting the known initial amount of DHBA (internal 
standard) in 6  ml of homogenizing buffer. The internal standard amount was 
multiplied by the ratio of the areas under the NE, EPI and DA peaks to the area 
under the DHBA peak, and by the ratio of the DHBA response factor to response 
factors for each of the catecholamines. For example, if a chart trace indicated an 
area under a NE peak of 50 volt«seconds and an area for DHBA of 75 
volt«seconds, with response factors of 2.53 volt«seconds/ng NE and 3.12 
volt«seconds/ng DHBA and an initial amount of DHBA of 300 ng, then 
NE = 300 ng •  (50 /  75) •  (3.12  /  2.53) = 247 ng.
The absolute amount of catecholamine was calculated as ng catecholamine per 
g tissue.
Materials
0 . 1  M Perchloric Acid (HCI04): Dilute 17.1 ml of 70% (concentrated) H C I0 4  to 2  
liters.
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Artificial Cerebrospinal Fluid (aCSF): Into a 100 ml volumetric flask put 1.4960g 
NaCI, 0.0388g KCI, 0.0382g CaCI2, 0.0366g MgCI2, 0.3360g N aH C 03, 
and 0.0697g Na2 H P 0 4. Dilute to the mark and stir until dissolved. Dilute 
this solution 1 : 1  when preparing agents in this vehicle.
Carrier free monoiodinated 1 2 5 l-[sar1 ,ile8]-angiotensin II: supplied by Dr. Robert 
Speth, was prepared as described previously (Speth etai., 1987).
Catecholamine Standard Solutions:
DHBA (100mg/L): Dissolve 16mg DHBA*HBr into 100 ml of 0.1 M 
perchloric acid (H C I04).
NE (75 mg/L) /  EPI (25 mg/L): Dissolve 14.2 mg norepinephrine bitartrate 
and 4.6 mg epinephrine bitartrate into 100 ml of 0.1 M perchloric 
acid (H C I04).
(100 ng DHBA, 75 ng NE, 25 ng EPI, 100 ng D A /m l): Combine 100 pL of 
each of the proceeding catecholamine standard solutions and dilute 
to 100 ml with 0.1 M perchloric acid (H C I04).
Homogenizing Solution: Combine 14.15 g/L monochloroacetic acid, 4.5 g/L
sodium hydroxide and 0.75 g/L disodium EDTA. Dissolve and adjust the 
pH to 3.00 - 3.05 with solid monochloroacetic acid or sodium hydroxide. 
Add pargyline to 350 pM (68.5 mg/L).
HPLC Mobile Phase: Dissolve 14.15 g/L monochloroacetic acid, 4.5 g/L sodium 
hydroxide and 0.75 g/L disodium EDTA. Adjust the pH to 3.00 to 3.05
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using solid monochloroacetic acid or sodium hydroxide. Add 65 mg/L 
sodium octyl sulfate.
Phosphate Buffered Saline: Add 8.5 g/L sodium chloride to 10 ml/L 500 mM 
sodium phosphate dibasic. Adjust pH to 7.2 to 7.3.
Subbing Solution: To 500 ml of water, add 5 g gelatin. Warm to dissolve but do 
not exceed 60°C. To 500 ml of water, add 0.5 g chromium potassium 
sulfate (CrK(S0 4 )2 :1 2 H20 ). After both solutions have dissolved, mix 
together and filter. Add thymol to preserve and refrigerate. Warm to room 
temperature before using and filter after each use.
Thionin staining solution: To 600 ml boiling water, add 3.6 ml glacial acetic acid, 
1.0 g thionin and 3.2 g Sodium Acetate (0.8%). When dissolved, add 400 
ml deionized water and adjust the pH to 4.5 with 10 N Sodium Hydroxide. 
Losartan potassium and PD123177 were supplied by Dr. Ronald Smith of 
DuPont (Wilmington, DE). Angiotensin peptides were obtained from Bachem 
(Torrance, Ca). Glacial acetic acid (A38c-212), EDTA, ethyl alcohol (A962p-4), 
sodium chloride (S671-3), sodium hydroxide (S-318), sodium phosphate dibasic 
(BP-331-1) and monobasic (S381), thionin stain (T-409), trichloroacetic acid 
(A176), and xylene (X3s-4) were obtained from Fisher Scientific (Pittsburgh, PA).
Amastatin (A-1276), bacitracin (B-0125), bestatin (B-8385), BSA (A-7906; 
albumin, bovine, fraction V), catecholamine standards (dihydroxybenzylamine -  
DHBA, epinephrine, norepinephrine, and dopamine), dithiothreitol (DTT, D-0632), 
pargyline (P-8013), 1,10 phenanthroline (P-1294), phenylmethylsulfonyl fluoride
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(PMSF, P-7626), sigmacote (SL-2), and trizma base (T-1503) were obtained 
from Sigma Chemical Co. (St. Louis, MO).
Leupeptin was obtained from Cambridge Research Biochemicals, Inc. 
(Wilmington, DE). Eukitt mounting medium was obtained from Aldrich chemical 
company (Milwaukee, Wl). Sodium octyl sulfate, rapid fixer, D-19 developer, and 
Photo Flo were obtained from Kodak-Eastman chemical company (Rochester, 
NY).
Guide cannula (22 ga cut 5 mm below pedestal), internal cannula (28 ga 
to fit guide with 1 mm projection), dummy cannula, cannula connectors, drill bits 
(for 0-80 screws), and jeweler’s screws (2.4 mm length, 0-80 x 3/32) were 
obtained from Plastics One Inc. (Roanoke, Va).
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CHAPTER 4
EVALUATION OF BUFFER CONSTITUENTS FOR DIFFERENTIAL EFFECTS 
ON 125I[SAR\ ILE8]-ANGIOTENSIN II BINDING AT A ^  AND AT2 RECEPTORS
IN THE RAT BRAIN
Introduction
Two subtypes of angiotensin II (All) receptors have been identified 
(Whitebread etai., 1989; Chiu etai., 1989a). The A ^  receptor subtype is 
differentiated by high affinity (IC 5 0  = 10 ‘8 M) for losartan (DuP753) and similar 
compounds, and relatively low affinity for CGP 42112A and PD123177 (IC50 = 
10"4  M). These compounds show the opposite pattern of selectivity for the 
receptor subtype designated AT2. Receptor autoradiographic techniques have 
confirmed the presence of both All receptor subtypes in discrete nuclei within the 
brain (Rowe etai., 1990c; Gehlert etai., 1990; Wamsley etai., 1990; Song etai., 
1992; Tsutsumi and Saavedra, 1992).
Several laboratories using membrane preparations or receptor 
autoradiography have employed a variety of procedures to investigate All binding 
with the implicit assumption that the basic methodology does not have a 
detrimental effect on binding to the All receptors of interest. This has not always 
been the case. For example, early studies indicated that sulfhydryl reducing
32
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agents were required to protect the radioligand from degradation (Glossman et 
a i,  1974; Bennett and Snyder, 1976) and they increased binding affinity for 125l- 
All in brain tissue (Chen et at., 1982; Printz, 1987). Thus sulfhydryl reducing 
agents were widely used in binding assays for brain tissue until it was revealed 
that they severely impair binding specifically at AT, but not AT2 receptors 
(Whitebread e ta i ,  1989; Chiu etai., 1989b; Speth e ta i ,  1991). Accordingly, 
most investigators now exclude sulfhydryl reducing agents when studying All 
receptors.
Most investigators are in general agreement with respect to localization 
and distribution of All receptor subtypes in brain tissue and the relative affinities 
of various ligands at AT-i and AT2  sites. However, subtle differences are apparent 
with respect to relative binding density among brain nuclei in autoradiographic 
studies. Further, we have reported that the radioligand 125l-[sar\ile8]-AII 
(125I-SIAII) has a fourfold selectivity for brain ATi binding sites (Rowe e ta i ,
1992) which is not corroborated by other investigators (Chang e ta i ,  1990; 
Obermuller e ta i ,  1991). Prompted by the precedent set with sulfhydryl reducing 
agents, we became concerned that different buffer constituents, used in binding 
assays in different laboratories, might affect binding differentially at ATi and AT2 
sites. Inclusion or exclusion of such a factor in incubation cocktails might alter 
results obtained in different laboratories. We began by investigating the 
peptidase inhibitors used routinely in our autoradiographic studies, bacitracin and
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EDTA, and then evaluated phenanthroline and BSA, which have been used by 
other investigators (Koziarz and Moore, 1989; Chang etai., 1990).
Design
Evaluation of EDTA and Bacitracin
Studies in our laboratory have routinely used buffer containing 150 mM 
NaCI, 50 mM sodium phosphate (pH=7.1-7.2), 5 mM disodium ethylenediamine 
tetraacetate (EDTA), and 0.1 mM bacitracin. Sets of six adjacent sections were 
prepared from each of 6  rat brains. These were incubated either in the above 
buffer (containing EDTA and bacitracin), a buffer from which bacitracin was 
omitted, and a buffer from which EDTA was omitted. Total and nonspecific 
binding were determined for each of the three buffers by in vitro receptor 
autoradiography as described in Chapter 3 - Methods.
Evaluation of Phenanthroline and BSA
A second experiment compared our standard buffer (NaCI, NaP0 4 , EDTA, 
and bacitracin) versus a buffer in which EDTA and bacitracin were replaced with 
1,10 phenanthroline (5x1 O'4  M) and BSA (0.2%), and one in which no peptidase 
inhibitors were present (EDTA and bacitracin were omitted). Sets of six adjacent 
sections prepared from each of 5 rat brains as described above were incubated 
in each of the 3 study buffers with and without an excess of unlabelled All. Again, 
specific binding was assayed by in vitro receptor autoradiography.
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Binding was also compared in buffers containing phenanthroline or BSA 
alone (versus phosphate-saline buffer, N=6 ) at the nucleus of the solitary tract 
(AT-i) and the inferior olivary nucleus (AT2).
Screening of Individual Buffer Constituents
To determine the individual effects on A ^  and AT2 binding of additional 
buffer constituents, total binding (N=3) was determined in a series of 6  adjacent 
brain sections. Total 125I-SIAII binding in control buffer (NaCI, N aP 04) was 
compared to total binding in the presence of individual peptidase inhibitors 
(dithiothreitol (DTT), 5 mM; PMSF, 1 mM; amastatin, 1.25 mg/L; bestatin, 1.25 
mg/L; leupeptin, 1.25 mg/L). Total binding was determined by in vitro receptor 
autoradiography for predominantly A ^  and AT2 nuclei.
Data Analysis and Statistics
Brain nuclei were selected and categorized by subtype predominance 
(>90% ATi or AT2) based on a previous study (Rowe etal., 1992) to facilitate 
comparisons of buffer effects on the two subtypes. ATi nuclei used include the 
piriform cortex (PC), suprachiasmatic nucleus (SCh), medial pre-optic nucleus 
(MnPO), ventral hippocampus (Vhip), paraventricular nucleus of the 
hypothalamus (PV), and the anterior pituitary (Pit). The AT2  nuclei used are the 
medial geniculate nucleus (MG), superior colliculus (SC), subthalamic nucleus 
(STh), lateral septum (LS), and the mediodorsal thalamus (MD). Subtype 
selective competitors were not used for this study.
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For each experiment, buffer effects on binding at each nucleus and 
recovery of intact radioligand were evaluated by a repeated measures analysis of 
variance and a modified Newman-Keuls test according to Winer (1971).
Results
Table 4-1A describes radioligand integrity after incubation with brain slices 
as a percent of intact radioligand prior to incubation in three buffers differing with 
respect to the presence of EDTA and bacitracin. HPLC analysis determined 
nearly complete recovery of intact 1 25I-SIAII from buffer containing both bacitracin 
and EDTA and in buffer containing only bacitracin following incubation of rat 
brain slices. However, intact radioligand recovery was significantly decreased 
(p<0.05) in the absence of bacitracin. Table 4-1B compares 125I-SIAII binding at 
rat brain nuclei in these three buffers. Figure 4-1 depicts specific binding as a 
percent of specific binding in buffer containing both EDTA and bacitracin at 
predominantly A L  and AT2 nuclei. The exclusion of EDTA consistently caused a 
significant (p<0.01) reduction in specific 125I-SIAII binding in all A ^  and AT2 
predominant brain nuclei studied, with an average reduction of approximately 
40%. Non-specific binding (not illustrated) was also consistently lower at all 
nuclei, averaging 17% less, with the omission of EDTA, but the effect was 
significant at only three nuclei. The exclusion of bacitracin had no effect on 
specific or non-specific binding at either category of brain nuclei.
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TABLE 4-1. 125I-[SAR\ILE8]-AII RECOVERY AND SPECIFIC BINDING IN 
BUFFERS CONTAINING BACITRACIN AND/OR EDTA
+Bac
(-EDTA)
+EDTA
+8ac
+EDTA
(-Bac)
A. Radioligand Recovery 98 ± 3% ns 98 ±1% • 83 ± 7%
B. Radioligand Binding
Predominantly Nuclei:
Piriform Cortex 311 ± 72 •  * 611 ±134 ns 667 ±171
Suprachiasmatic n. 7 1 5 ± 59 * * 1049± 79 ns 953± 63
Median Preoptic 493 ± 98 887 ±111 ns 878± 79
Ventral Hippocampus 496 ± 67 •  * 700 ±101 ns 679 ± 70
Paraventricular n. 604 ± 73 • * 1140± 87 ns 1014± 87
Anterior Pituitary 2787 ± 359 * * 4690 ± 484 ns 4368 ±419
Predominantly AT2 Nuclei:
Mediodorsal Thalamus 226 ± 1 9 * * 372 ± 25 ns 346 ± 27
Subthalamic n. 581 ± 42 * * 887 ± 80 ns 805 ± 52
Medial Geniculate n. 318 ± 5 9 * * 468 ± 56 ns 441 ± 65
Superior Colliculus 304 ± 28 * * 577 ± 56 ns 591 ± 52
Lateral Septum 141 ± 2 4 « • 260 ± 24 ns 286 ± 24
Binding values are reported in fmoles/gram of brain tissue ± SEM (n=6 ). * and ** 
denote significant differences (p<0.05 and p<0.01, respectively) between values 
in adjacent columns.
Because our recoveries exceeded 80% with reduced peptidase inhibition, 
we elected to utilize a minimal control buffer in the evaluation of additional buffer 
constituents. Table 4-2 summarizes radioligand integrity (A) and binding 
determinations (B) in buffers containing bacitracin and EDTA, no peptidase 
inhibitors, or phenanthroline and BSA. The radioligand was well preserved by the 
bacitracin/EDTA buffer and by the phenanthroline/BSA buffer. Intact 125I-SIAII 
recovery was significantly reduced (but still exceeded 80%) in the buffer 
containing no peptidase inhibitors, consistent with the first experiment showing 
that deletion of bacitracin from the buffer led to increased radioligand
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Binding at AT, Nuclei
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Figure 4-1. Effects of EDTA and bacitracin on specific 1 25|_siAII binding. The  
100% line represents specific binding in the presence of bacitracin and EDTA, 
while white bars depict binding in the absence of EDTA and the black bars depict 
binding in the absence of bacitracin. Significant differences (p<0.01) from the 
control line are noted. Data are expressed as means ± SEM (N=6 ). 
Abbreviations: PC, piriform cortex; S.CH., suprachiasmatic n.; MnPO, median 
preoptic n.; V.Hipp., ventral hippocampus; PV, paraventricular n.; Pit., anterior 
pituitary; MD, mediodorsal thalamus; S.Th., subthalamic n.; MG, medial 
geniculate n.; SC, superior colliculus; and LS, lateral septum.
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TABLE 4-2. SPECIFIC 125l-[SAR1 ,ILE8]-ANGIOTENSIN II RECOVERY AND 
SPECIFIC BINDING IN BUFFERS CONTAINING PHENANTHROLINE/BSA, 
BACITRACIN/EDTA, OR NO INHIBITORS
+Phen
+BSA
+Bac
+EDTA
no
inhibitors
A. Radioligand 
Recovery 94 ± 4% Ns 97 ± 1% * 86 ± 4%
B. Radioligand Binding
Predominantly Ati Nuclei:
Piriform Cortex 1061 ± 225 ns 1026 ±273 5 7 8 ± 112
Suprachiasmatic n. 1553 ± 334 ** 1072 ±248 * 769 ±186
Median Preoptic 1331 ± 217 • 1024 ±170 * 6 2 2 ± 51
Ventral Hippocampus 1055 ± 117 • -» 817 ±100 ** 4 8 5 ± 43
Paraventricular n. 1542 ± 191 * * 1015 ± 124 5 9 4 ± 89
Anterior Pituitary 6285 ±1449 ** 4100 ±780 * 2598 ± 750
Predominantly AT2 Nuclei:
Mediodorsal Thalamus 167 ± 8 * * 289 ± 13 * 240 ± 21
Subthalamic n. 590 ± 75 825 ± 93 « * 492 ± 48
Medial Geniculate n. 245 ± 18 * « 319 ± 24 * * 189 ±20
Superior Colliculus 347 ± 48 • * 458 ± 62 •  » 253 ± 33
Lateral Septum 152 ± 9 « « 239 ± 32 * * 115 ± 8
Binding values are reported in fmoles/gram of brain tissue ± SEM (n=5). * and ** 
denote significant differences (p<0.05 and p<0.01, respectively) between values 
in adjacent columns.
degradation. Figure 4-2 illustrates relative specific binding determinations in each 
of these buffers at predominantly ATi and predominantly AT2  nuclei. In the 
presence of both EDTA and bacitracin, binding was increased (compared to 
binding in the absence of inhibitors) by an average of 39% at all brain nuclei 
surveyed irrespective of subtype composition. At all predominantly A ^  nuclei 
(except the piriform cortex), binding was significantly higher in the 
phenanthroline/BSA buffer compared to both other buffers. In contrast, 125I-SIAII 
binding at AT2  nuclei in the phenanthroline/BSA buffer was significantly lower
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Figure 4- 2. Effects of phenanthroline and BSA on specific 1 2 5 I-SIAII binding. 
The 100% line represents specific binding in the presence of bacitracin and 
EDTA, while the white bars depict binding in the absence of peptidase inhibitors 
and the black bars depict binding with phenanthroline and BSA. Significant 
differences (* p<0.5, and ** p<0.01) from the 100% control line are noted. Data 
are expressed as means ±  SEM (N=5). See brain nuclei abbreviations in the
legend of Figure 4-1.
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than EDTA/Bacitracin and similar to the buffer with no additions. Thus, the 
EDTA/bacitracin buffer affected binding consistently at ATt and AT2 binding sites 
while the phenanthroline/BSA combination enhanced binding preferentially at 
A ^  sites. Non-specific binding (not presented) was similar in all three buffers and 
was approximately 10-15% of total binding. Phenanthroline and BSA were 
evaluated individually at the nucleus of the solitary tract and the inferior olivary 
nucleus in each of 6  rat brains. Specific binding at the nucleus of the solitary tract 
(AT!) was 782 ± 52 fmol/g in phosphate-saline buffer, 1224 ±  93 with BSA (57% 
increase, p<0.01), and 1122 ± 7 8  with phenanthroline (43% increase, p<0.01). 
Specific binding at the inferior olivary nucleus (AT2) was 410 ±  30 fmol/g in 
phosphate-saline buffer, 356 ±  23 with BSA (NS), and 325 ± 24 with 
phenanthroline (21% decrease, p<0.01). Thus, the enhancement seen with 
phenanthroline and BSA at A ^  nuclei in the previous experiment is due to 
individual contributions by both phenanthroline and BSA.
Additional buffer constituents were screened and the results are 
summarized in table 4-3. Radioligand recoveries were significantly less than 
1 0 0 % (after tissue incubation compared to before tissue incubation) in the 
presence of PMSF, amastatin, or leupeptin. Similarly, recovery in the control 
buffer (saline-phosphate) was 76 ±  9.1 % (p<0.05). Only DTT seemed to offer 
substantial protective effects.
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TABLE 4-3. 1 2 5 I-[SA R \ ILE8]-ANGIOTENSIN II RECOVERY 
AND TOTAL BINDING (RELATIVE TO CONTROL) IN THE  
PRESENCE OF INDIVIDUAL PEPTIDASE INHIBITORS.
DTT PMSF Amastatin Bestatin Leupeptin
A. Radioligand Recovery
Significance
87 ± 5.8% 69 ±4 .2 % 77 ± 6.2% 76 ±11 .0%  73 ± 1 0 .9 %
(vs. 1 0 0 %) Ns P<0.01 P<0.05 ns P<0.05
B. Total Binding (% Control) 1
Predominantly A ^  Nuclei
PC 14 ± 0.05 1 0 2  ± 0 . 2 107 ± 1 .6 115 ± 6 . 1 124 ± 10.9
Pit 1 2  ± 2 . 1 104 ± 1 .2 96 ± 3.8 108 ± 5 .3 99 ± 4.2
PV 24 ± 2 .8 103 ±1.1 105 ± 3 .4 107 ± 9 .2 106 ± 9.2
SCh 13 ± 0 .8 95 ±5.1 97 ± 3.4 1 1 0 ± 6 .3 1 0 2  ± 6.7
VHipp. 14 ± 2 .2 98 ±4.1 96 ±4.1 104 ± 2 . 1 1 1 1  ± 7.6
ATt Mean 15 ± 2 .2 1 0 0  ± 1 . 8 100 ± 2 .5 109 ± 1 .7 108 ± 4.4
Predominantly AT2 Nuclei
LS
MD
MG
SC
STh.
131 ±1 9 .6  
124 ± 5.4 
111 ± 8.1 
139 ±25 .0  
109 ± 7.0
112 ± 4 .4  
102 ± 1 .7  
108 ± 7 .5  
94 ±  5.6 
107 ± 6 .2
117 ± 5 .7
109 ± 1 .4  
97 ± 7.6 
95 ± 3 .5
110 ± 7 .4
130 ±17 .2  
116 ± 4.5 
114 ± 10.5
116 ± 3.4
117 ± 14.4
150 ± 2 5 .7  
119 ±  1.5 
119 ± 13.8 
132 ± 5.6 
119 ± 8.3
AT2 Mean 123 ± 5.8 105 ±3.1 106 ± 4 .2 119 ± 2.8 128 ± 6.2
Selectivity
(AT 1 vs. AT2) P<0.05 ns ns ns ns
1 Abbreviations: piriform cortex (PC), pituitary (Pit), paraventricular n. of the 
hypothalamus (PV), suprachiasmatic n. (SCh), ventral hippocampus (VHipp.), 
lateral septum (LS), mediodorsal thalamus (MD), medial geniculate (MG), 
superior colliculus (SC) and subthalamic n. (STh.).
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Binding values are expressed as percent of binding observed in control 
buffer to facilitate comparisons between nuclei, in order to ascertain the 
selectivity (differential effects on binding with respect to receptor subtype), the 
effect on binding at predominantly ATi nuclei is compared to that observed at 
predominantly AT2 nuclei. Dithiothreitol (a sulfhydryl reducing agent) altered 
binding as expected, markedly inhibiting ATi binding while enhancing binding at 
AT2  sites. This pattern produced a significant difference in relative binding at ATi 
versus AT2 sites. Relative binding in the presence of PMSF, amastatin, bestatin 
and leupeptin was not significantly different with respect to receptor subtype. 
Therefore, these peptidase inhibitors do not differentially affect binding at ATt 
and AT2  receptors.
Discussion
Analysis of receptor binding studies ideally presupposes that ligand and 
receptor metabolism do not occur. Selection of incubation constituents is often 
made to accomplish this goal with the expectation that these constituents will not 
interfere with the receptor-ligand reaction. The susceptibility of angiotensin II and 
its analogues to metabolism dictates the use of peptidase inhibitors in incubation 
cocktails. Some laboratories use radioligands such as 125I-SIAII which are 
relatively resistant to aminopeptidase action. There is considerable variation in 
the selection of inhibitors for other peptidases and for other ionic buffer 
constituents. With regard to the criterion that constituents must not interfere with
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binding, many of these procedures were established before the discovery of All 
receptor subtypes and it is now apparent that this criterion was not satisfied 
independently for both ATi and AT2  binding reactions. This important 
consideration was emphasized by the discovery that sulfhydryl reducing agents 
selectively interfere with binding at ATt sites (Whitebread etal., 1989; Chiu et 
al., 1989b; Speth etai., 1991).
In our studies of rat brain All receptor binding we have noted some subtle 
differences in data reported by various laboratories. For example, estimates of 
receptor subtype proportions within brain nuclei are not entirely consistent (Rowe 
e ta i ,  1992; Gehlert etal., 1990; Song e ta i ,  1992; Tsutsumi and Saavedra, 
1992). Moreover, we find that 1 2 5 I-SIAII shows some selectivity for brain ATt 
receptors (Rowe et a i,  1992) which is at variance with findings from some 
laboratories (Chang e ta i ,  1990; Obermuller e ta i ,  1991) but is similar to the 
findings of Tsutsumi and Saavedra (1992) for 125l-sar1-AII. It occurred to us that 
such discrepancies might result from one or more peptidase inhibitors exerting 
differential effects on binding at ATi and AT2  receptors similar to that observed 
for sulfhydryl reducing agents. Table 4-4 itemizes incubation constituents used 
by several laboratories.
Comparison of binding at A ^  and AT2 sites was accomplished by sorting 
brain nuclei by predominant subtype (>90%) established in a previous study 
(Rowe e ta i,  1992). Thus, the results were not obtained from completely
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TABLE 4-4. ITEMIZED LISTING OF BUFFER  
CONSTITUENTS FOR SEVERAL LABORATORIES.
Reference1:
1 2 3 4 52 6* r
Sodium phosphate (mM) 50 50 10 10 10
Tris (mM) 50 50
NaCI (mM) 150 150 150 120 100 125 150
MgCI2 (mM) 10 6.5
EDTA (mM) 5 5 5 5 1 5
EGTA (mM) 5
Bacitracin (mM) 0.1 0.4 0.07 0.1
BSA (%) 0.4 0.2 0.2 0.2 0.2 0.2
Phenanthroline (mM) 0.09 1
1 References: 1> Rowe etal., 1992; 2> Gehlert etal., 1990; 3> Song etal., 1992; 4> Tsutsumi and 
Saavedra, 1992; 5> Chang etal., 1990; 6> Obermuller etal., 1991; 7> Koziarz and Moore, 1989. 
Additional buffer constituents:2 0.2 mg/ml soybean trypsin inhibitor, 0.1 mM phenylmethylsulfonyl- 
fluoride;3 1.25 pg/ml each antipain, phosphoramidon, leupeptin, pepstatin A, bestatin and amastatin; 
i  1 mM phenylrr.ethylsulfonylfluoride.
homogeneous receptor subtype populations. This approach was selected 
because utilization of subtype selective antagonists to mask each receptor 
subtype would introduce uncertainties with respect to possible differential 
metabolism or binding characteristics of antagonists in each experimental 
situation. We believe the approach is justified by the compelling internal 
consistency observed within the A ^  and AT2 categories.
We first evaluated the buffer constituents routinely used in our laboratory, 
EDTA and bacitracin. Addition of EDTA quantitatively increased specific binding 
by approximately 70% equally at both AT-i and AT2 binding sites. This is
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interesting because radioligand degradation was unaffected by the absence or 
presence of EDTA, suggesting that EDTA affects binding in a manner unrelated 
to radioligand preservation. Three possible mechanisms might be considered:
1) EDTA chelates ions that hamper the interaction of 125I-SIAII with both All 
receptors, 2) EDTA interacts directly with the radioligand (and/or receptors) to 
enhance binding affinity, or 3) EDTA inhibits metalloproteases that degrade both 
ATt and AT2 receptors equally. The effect of EDTA on non-specific binding is 
similar. If we assume this is not residual specific binding, then EDTA affects 
125I-SIAII but not All receptors.
Bacitracin appears to be important for preserving radioligand, but had no 
effect on specific or non-specific binding. However, radioligand metabolism in the 
absence of bacitracin was minimal (13-17%) which probably accounts for our 
inability to observe differences in radioligand binding in the presence and 
absence of bacitracin. The presence of bacitracin may assume greater 
importance for the preservation of other angiotensin peptides and in binding 
assays where tissue/ligand ratios are higher. Parenthetically, concentrations of 
bacitracin greater than 0.1 mM inhibit 125I-A1I binding in rat brain homogenates 
(Speth, unpublished observation).
Some investigators use phenanthroline (0.1-1.0 mM) and BSA (0.2%) in 
binding assays (table 4-4). Koziarz and Moore (1989) evaluated 125I-AII binding 
with bovine membrane preparations in the absence and presence of
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1,10-phenanthroline (1 mM). Phenanthroline completely eliminated 125I-AII 
degradation without affecting binding. Since similar results were obtained for both 
uterine (AT2 predominant) and aortic (A ^  predominant) preparations, we infer 
that binding was not differentially affected at A ^  and AT2 sites. These interesting 
observations prompted us to include phenanthroline in our autoradiographic 
system. We used a concentration of 0.5 mM phenanthroline which is lower than 
that used by Koziarz and Moore (1 mM) but higher than that used by Chang et al. 
(1990), (0.09 mM). Radioligand recovery in this study was 86.7%  in the absence 
of inhibitors compared to 94.3% (not significantly different) in the presence of 
phenanthroline and BSA. The excellent radioligand recovery in the absence of 
inhibitors in our experiments may be attributed to the aminopeptidase resistance 
of the sarcosine substituted radioligand and the low tissue/radioligand ratio in 
these autoradiographic studies. Interestingly, however, phenanthroline and BSA 
had marked differential effects on binding at ATi nuclei as compared to AT2 
nuclei.
Addition of phenanthroline and BSA affects binding at both A ^  and AT2 
sites in a manner that is dissimilar to EDTA. Phenanthroline chelates metal ions 
(Mertell and Calvin, 1956), but none that are not also chelated by EDTA. Thus, 
the chelating properties of phenanthroline are unlikely to account for the 
differential effects on binding. It is also possible that BSA contributes to the 
observed effects. The ATt receptor has disulfide bonds in its extracellular domain
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(Murphy etal., 1991; Sasaki etal., 1991) that are crucial for binding (Whitebread 
etal., 1989; Chiu etal., 1989b). Since BSA is stabilized by 17 disulfide bonds 
(Budavari, 1992) it might serve as an antireductant and preserve the tertiary 
structure of the ATi receptor. W e have not attempted a systematic analysis of 
each buffer constituent employed by multiple laboratories but we do provide 
evidence that procedural differences are likely to account for reported differences 
in binding characteristics.
This study indicates that degradation of 125I-SIAII is minimal (<17%) in the 
complete absence of peptidase inhibitors in our autoradiographic procedures. It 
does not follow, however, that the observation is applicable to non- 
autoradiographic binding studies or to autoradiographic studies using non- 
sarcosine angiotensin peptides or to studies with higher tissue/incubation 
medium ratios. Inclusion of bacitracin or phenanthroline/BSA leads to near total 
recovery of radioligand. EDTA enhances binding but does so uniformly at both 
A ^  and AT2 sites. In contrast, phenanthroline and/or BSA markedly enhance 
binding at ATi sites but not at AT2 sites. It is clear that buffer constituents affect 
binding at A ^  and AT2 sites by mechanisms that are independent of radioligand 
metabolism. Therefore, relative binding characteristics between A ^  and AT2 
receptor subtypes will necessarily differ and caution must be exercised in 
comparing data from different laboratories.
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LOCALIZATION AND SUBTYPE CHARACTERIZATION O F ANGIOTENSIN II
RECEPTORS IN THE NORMOTENSIVE AND SPONTANEOUSLY  
HYPERTENSIVE HAMSTER
Introduction
The presence of angiotensin II (All) receptor subtypes has been confirmed 
in tissue homogenates of rat, rabbit and monkey brains (Chang and Lotti, 1991), 
and classification of individual brain nuclei by receptor subtype has been 
determined in the rat (Rowe et al., 1990c; 1991; 1992). Subtype classification of 
individual brain nuclei remains undetermined for other species, but binding sites 
have been mapped autoradiographically to individual brain nuclei in the sheep 
(McKinley et al., 1986), rabbit (Mendelsohn et al., 1988), dog (Speth et al., 1985), 
and human (McKinley et al., 1987). Some species differences are evident but 
binding site distributions are generally similar (Mendelsohn et al., 1990). The 
purpose of the first part of the present study is to define the distribution of All 
receptors in the hamster brain, and further, to classify each receptor population 
by receptor subtype.
Genetic models of hypertension in the rat are associated with 
disturbances in the brain angiotensin system. For example, centrally
49
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administered All stimulates a larger blood pressure increase in spontaneously 
hypertensive rats (SHR) than in normotensive control rats (Hoffman etal., 1977), 
and saralasin administered centrally reduces the blood pressure of SHR but not 
control rats (Hutchinson etal., 1975; Phillips etal., 1977). Further, there is a 
greater All-like immunoreactivity (Weyhenmeyer and Phillips, 1982), and 
quantitative autoradiographic studies have shown significantly higher All binding 
in SHR brains (Hwang et al., 1986; Gehlert etal., 1986b). W e therefore 
compared 125l-[sar1,ile8]-AII (125I-SIAII) binding in a model of genetically 
hypertensive hamster (Joyner etal., 1988) with normotensive controls.
Design
The first experiment was designed to determine which hamster brain 
nuclei contain All receptors, and further to characterize each receptor population 
by All receptor subtype. Brains from 4 golden Syrian hamsters (102-120 g) were 
prepared as described in methods (in vitro receptor autoradiography). Incubation 
mediums consisted of buffer with 125I-SIAII (350-420 pM) alone, with losartan 
(10'5 M), with PD123177 (10‘5 M), or with All (10'6 M). Tissue sections from two 
animals were also incubated in the presence of both losartan and PD123177 
(10'5 M). Receptor subtype distribution was determined by comparing specific 
binding of 125I-SIAII in the presence of losartan or PD123177 with specific binding 
in the absence of competitors. The subtype selective compound losartan 
competes for 125I-SIAII binding at the A ^  but not at the AT2 subtype while 
PD123177 competes selectively for the AT2 binding site.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
51
A second experiment evaluated 125I-SIAII binding in a hamster model of 
genetic hypertension (Joyner etal., 1988). Brain sections from 4 normotensive 
(128-133 g) and 4 hypertensive (117-144 g) hamsters were incubated with 
125I-SIAII (262-266 pM) as described in methods (in vitro receptor 
autoradiography). Each brain from a hypertensive hamster was processed and 
incubated concurrently with a brain obtained from the normotensive control 
strain.
Results
Sets of adjacent sections were incubated with 125I-SIAII in the presence 
and absence of the All subtype selective compounds losartan (ATi selective) and 
PD123177 (AT2 selective). A typical example obtained at the level of the 
hypothalamus is illustrated by the autoradiograms in Figure 5-1. Losartan 
(10'5 M) competed effectively for binding sites in the hippocampus, choroid 
plexus, and the paraventricular nucleus of the hypothalamus (ATt sites), but not 
at the medial habenular nucleus (AT2 site). Competition with PD123177 (10‘5 M) 
produced the opposite pattern, i.e. it competed substantially for 125I-SIAII binding 
at the medial habenular nucleus, but not at the other structures. The 125I-SIAII 
binding was substantially displaced in all structures in sections incubated with 
both subtype selective compounds and produced autoradiograms very similar to 
those of sections incubated with All (1CT6 M). Similar results were obtained for 
various brain nuclei (autoradiograms not illustrated) which were quantitated and 
summarized in Table 5-1. A reciprocal competition pattern between the two
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Figure 5-1. [125l][Sar1,lle8]-angiotensin II (125I-SIAII) binding with subtype selective 
competitors in adjacent hamster brain sections. A: total 125I-SIAII binding without 
competitors; B: thionin stained section (Bar = 2 mm); C: sites insensitive to 
losartan (10*5 M) [medial habenula (MHb)]; D: competition with both losartan (10‘5 
M) and PD123177 (10'5 M); E: sites insensitive to PD123177 (10*5 M) 
[hippocampus (Hip), choroid plexus (ChP), and the [paraventricular nucleus of 
the hypothalamus (PV)]; F: non-specific binding not displaced by Ang II (lO"6 M).
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subtype selective compounds was evident in all brain regions. In some brain 
nuclei, competition by the combination of both subtype selective compounds was 
slightly more effective than All. This is reflected by negative specific binding 
values reported in Table 5-1.
Figures 5-2 through 5-6 illustrate 125I-SIAII binding without competitors for 
a selection of brain regions listed in Table 5-1. Each autoradiogram is 
accompanied by the adjacent thionin stained section to aid in the verification of 
structures.
Hindbrain:
Figure 5-2 illustrates 125I-SIAII binding in the dorsal motor nucleus of the 
vagus (DMV), the nucleus of the solitary tract (NTS), and the spinal trigeminal 
tract. All three regions contain predominantly ATi receptor sites (Table 5-1). 
Binding to A ^  sites is also evident in the area postrema (not illustrated) and is 
particularly dense in the paramedial segment of the NTS. The remaining 
subdivisions of the hamster NTS show modest binding compared to strikingly 
dense binding in the DMV. Interestingly, the DMV of the hamster was unique in 
that approximately one-fifth of specific 125I-SIAII binding was not displaced by 
either losartan or PD123177 at the concentrations used. The lower panel in 
figure 5-2 also shows binding in the choroid plexus (ChP) of the fourth ventricle 
and a diffuse AT 1 binding is barely discemable in the rostral portion of the 
ventrolateral reticular formation. There is a notable absence of 125I-SIAII binding 
in the inferior olive.
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TABLE 5-1. [125I][SAR1 ,ILE8]-ANGI0TENSIN II BINDING AT HAMSTER 
BRAIN NUCLEI WITH AND W ITHO UT SUBTYPE SELECTIVE COMPETITORS
Specific ’ “^ l- fsa r ’ .ile^-Angiotensin II bound Nonspecific
(fmoles/g tissue)1 Binding
Without W ith Losartan With PD123177 Losartan With All
Nucleus Competition (10-5 M) (10'5M) +-PD123177 l O ^ M
Pituitary 881±  69 312*73 (65%) 715±105 (19%) 67 ± 5 2 111 ±11
Subfornical Organ 1064±201 353±64 (67%) 715±110 (33%) -46 ± 59 119 ± 34
Median Preoptic n. 706± 90 159±24 (77%) 378± 94 (46%) - 1 3 * 2 3 73 ±11
Paraventricular n. 1263±140 197*52 (84%) 1213*121 (4%) -118 *  9 174 ± 18
Ventral Hippocampus 651± 79 92*26 (86%) 551 ± 5 9  (15%) - 1 6 *  5 99 ± 1 8
Nucleus Tractus
Solitarius 955± 48 362*44 (62%) 800± 78 (16%) 96 ±11 116 ± 8
Spinal Trigeminal n. 539± 38 169*18 (67%) 389± 35 (28%) 4.5 ± 11 68 ± 6
Pedunculopontine Tg. n. 596± 72 92*8.9  (85%) 479± 47 (20%) -19 ± 15 66 ± 1 2
Parabrachial n. 746± 15 231 ±22 (69%) 440± 22 (41%) 20 ± 8 73 ± 1 0
Locus Coeruleus 536* 19 365±13 (32%) 264± 60 (51%) 7 ±  6 54 ± 6
Inferior Colliculus 682± 74 494±47 (28%) 134± 18 (80%) 1 1 * 3 68 ± 7
Superior Colliculus 800* 48 686±37 (14%) 105± 14 (87%) 16 ±  17 58 ± 5
Lateral Septum 532± 67 481 ±73 (10%) 115± 23 (78%) 26 ± 2 3 70 ± 7
Medial Geniculate n. 655± 78 108±10 (84%) 484± 40 (26%) 11 ±  5 69 ± 5
Dorsal Motor n. Vagus 2184±122 636±45 (71%) 2093±137 (4%) 457 ± 36 238 ± 21
Peri-aqueductal Grey 445* 36 330±22 (26%) 147± 27 (67%) 1 0 ±  3 56 ± 8
Interpeduncular n. 821± 37 587±96 (29%) 96± 24 (88%) -9 ± 9 66 ± 1 7
Choroid Plexus 387* 42 100±15 (74%) 238± 54 (39%) 11 ± 4 61 ± 12
Medial Habenula 936± 95 894±94 (4%) 271 ± 17 (71%) 61 ± 3 6 53 ± 7
1 Values in parentheses represent the proportion of specific binding displaced by subtype 
selective competition. For some nuclei, total radioligand binding in the presence of both subtype 
selective antagonists was less than binding in the presence of unlabelled angiotensin II, 
producing negative specific binding values.
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Figure 5-2. Total 125I-SIAII binding (left panels) and adjacent thionin stained sections 
(right panels; Bar = 2 mm) at the nucleus o f the solitary tract (NTS), dorsal motor nucleus o f the 
vagus (DMV) and spinal trigeminal tract (SP5).
Figure 5-3. Total 125I-SIAII binding (left panels) and adjacent thionin stained sections (right 
panels; Bar = 2 mm) at the choroid plexus (ChP), nucleus tractus solitarius (NTS) and 
posterodorsal tegmental nucleus (PDTg).
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Figure 5-3 illustrates binding in the rostral NTS and the choroid 
plexus as it occurs throughout the fourth ventricle. The 125I-SIAII binding in 
pontine structures at the level of the genu of the seventh nerve includes diffuse 
binding in vestibular nuclei and denser binding associated with the locus 
coeruleus (LC) and the posterodorsal tegmental nucleus (PDTg). Binding sites in 
the locus coeruleus appear to be a substantial mixture of both ATi and AT2 sites 
(Table 5-1).
Midbrain:
The 125I-SIAII binding sites on the medial border of the inferior colliculus 
(Figure 5-4) are predominantly AT2. Figure 5-4 also illustrates binding sites in the 
parabrachial nucleus and the pedunculopontine tegmental nucleus. Binding in 
both nuclei is a mixture of ATt and AT2 sites with ATi predominating.
The top panel in Figure 5-5 demonstrates binding in the superior colliculus 
(SC), periaqueductal grey (PAG), interpeduncular nucleus (IP), the ventral 
portion of the caudal hippocampus (VH), and the anterior pituitary. A ^  binding 
sites are evident in the posterior segment only of the medial geniculate nucleus 
(MG, not illustrated). Diffuse, predominately AT2 binding is evident in the 
periaqueductal grey (PAG). Binding is conspicuously absent in the subthalamic 
nucleus of the hamster.
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Figure 5-4. Total 125I-SIAII binding (left panels) and adjacent thionin stained 
sections (right panels; Bar = 2 mm) at the inferior colliculus (IC), parabrachial 
nucleus (PB) and pedunculopontine tegmental nucleus (PPTg).
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Figure 5-5. Total 125I-SIAII binding (left panels) and adjacent thionin stained 
sections (right panels; Bar = 2 mm) at the superior colliculus (SC), periaqueductal 
grey (PAG), ventral hippocampus (VH), interpeduncular nucleus (IP), pituitary 
(Pit), subfornical organ (SFO) and median preoptic nucleus (MnPO).
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Forebrain
Figure 5-1 shows 12SI-SIAII binding in the hippocampus, medial habenular 
nucleus (MHb) and paraventricular nucleus (PV). The dense binding in the MHb 
is predominately AT2 , while the other structures represent mostly ATi binding 
sites as described above. Binding is notably absent at the suprachiasmatic 
nucleus, medial amygdala and lateral olfactory tract. Figures 5-5 and 5-6 
illustrate 125I-SIAII binding in the subfornical organ (SFO), median preoptic 
nucleus (MnPO), organum vasculosum of the lamina terminalis (OVLT) and 
lateral septum (LS). Binding was also observed in the supraoptic nucleus (not 
illustrated). Binding is absent in the piriform cortex while the striatum has diffuse 
but conspicuous binding (Figure 5-6).
Hypertensive Hamsters
Table 5-2 describes specific 125I-SIAII binding in the brain nuclei of 4 
hypertensive hamsters (systolic, 140-151 mm Hg) and 4 normotensive controls 
(systolic, 80-87 mm Hg). There were no significant differences in 125I-SIAII 
binding for any of the nuclei studied.
Discussion
The distribution of All receptors in the hamster brain is similar to that 
reported in the rat and other species. The similarities are particularly prominent in
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Figure 5-6. Total 125I-SIAII binding (left panels) and adjacent thionin stained 
sections (right panels; Bar = 2 mm) at the median preoptic nucleus (MnPO), 
organum vasculosum of the lamina terminalis (OVLT) and lateral septum (LS)
nuclei associated with cardiovascular or dipsogenic functions. For example, the 
SFO, OVLT, and MnPO have been linked to dipsogenic actions of All, and the 
SFO, OVLT, AP, SC, PAG, and NTS have been implicated in the mediation of 
pressor responses to All (Speth eta!., 1988). All of these brain nuclei contain 
high densities of All receptors in both hamster and rat. Other nuclei involved in 
cardiovascular function where dense 125I-SIAII binding is observed in both 
species include the PV, MnPO, and DMV. Recent studies have demonstrated
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TABLE 5-2. SPECIFIC 125I-[SAR1, ILEa]-ANGIOTENSIN II BINDING AT BRAIN 
NUCLEI OF NORMOTENSIVE AND HYPERTENSIVE HAMSTER STRAINS.
Normotensive Hypertensive 
Nucleus Hamsters Hamsters
Pituitary 479 ± 98 603 ± 32
Subfornical Organ 860 ± 223 905 ± 116
Median Preoptic n. 362 ± 71 285 ± 20
Paraventricular n. 764 ± 40 819 ± 70
Ventral Hippocampus 353 ± 26 371 ± 34
Nucleus Tractus Solitarius 559 ± 53 559 ± 53
Spinal Trigeminal n. 261 ± 19 263 ± 19
Pedunculopontine Tegmental n. 304 ± 32 249 ± 44
Parabrachial n. 466 ± 31 501 ± 48
Locus Coeruleus 227 ± 18 217 ± 30
Inferior Colliculus 271 ± 12 264 ± 36
Superior Colliculus 323 ± 36 347 ± 55
Lateral Septum 198 ± 29 210 ± 27
Medial Geniculate n. 213 ± 3 277 ± 35
Dorsal Motor n. of the Vagus 1429 ± 234 1454 ± 158
Peri-aqueductal Grey 159 ± 20 145 ± 19
Interpeduncular n. 453 ± 35 528 ± 78
Choroid Plexus 226 ± 41 166 ± 32
Medial Habenula 503 ± 58 407 ± 53
Organum Vasculosum of the 
Lamina Terminalis 791 ± 112 728 ± 120
blood pressure responses to All administered locally at the ventrolateral medulla 
(Muratani etal., 1991) of rats. Discemable but weak 125l-SIAIi binding is localized 
in this brain region of both the hamster and the rat.
At several nuclei, 125I-SIAII binding was notably different between species. 
For example, All receptors have been localized at the inferior olive, 
suprachiasmatic nucleus, subthalamic nucleus, medial amygdala, piriform cortex 
and various thalamic structures of the rat, but 125I-SIAII binding is conspicuously 
absent at these regions of the hamster brain. With the exception of the
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subthalamic nucleus and inferior olive of the human brain (Allen eta!., 1991), 
there are no reports of binding in these regions in other species either. There is 
particularly dense 125I-SIAII binding in the anterior pituitary of the rat, but 
relatively weak binding in the hamster. Binding in the hamster hippocampus is 
more extensive than that observed in the rat, and binding in the striatum of the 
hamster is more conspicuous than the rat. Binding in the DMV of the hamster is 
particularly dense. Intense binding observed in the interpeduncular nucleus and 
the medial habenula of the hamster was particularly interesting. All binding is 
minimal or absent at these nuclei in the rat brain, and unreported in other species 
with the exception of the interpeduncular nucleus of the rabbit (Mendelsohn et 
al., 1988) and human (Allen etai., 1991).
The medial habenula and interpeduncular nuclei communicate via the 
habenulopeduncular tract (Herrick, 1965; Contestabile and Villani, 1983). This 
system has connections to the olfactory and limbic system via several nuclei 
which also contain All receptors including: septum (Herkenham and Nauta,
1977), suprachiasmatic nucleus (of the rat) (Sofroniew and Weindl, 1978), locus 
coeruleus and dorsal tegmental region (Jones and Moore, 1977), central gray 
(Marchand e ta i ,  1980), and the ventral tegmental nucleus (Contestabile and 
Flumerfelt, 1981). The habenula may be important in linking olfactory sensory 
information with motor areas in the brainstem, or in mediating certain emotional 
behaviors (Crosby e ta i,  1962; Herrick, 1965; Woodbume, 1967). Lesions of the 
medial and lateral habenular nuclei result in the impairment of the ability of rats to
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find food via smell (Rausch and Long, 1971) and furthermore, lesions of the 
anterior olfactory nucleus are related to degeneration in the dorsomedial 
thalamus and habenula in the opossum (Ferrer, 1969). Perhaps All influences 
salt or water seeking behaviors via this system and species variations are related 
to differing physiological adaptations to respective natural environments.
The apparent absence of All receptors at the subthalamic nucleus, inferior 
olive, piriform cortex, medial amygdala, and suprachiasmatic nucleus in the 
hamster, but not in the rat is interesting. These structures process a variety of 
sensory information (Paxinos, 1985) and it is difficult to understand how these 
two species might function differently in this regard. However, the role of the 
suprachiasmatic nucleus in processing photoperiod information to influence 
circadian and reproductive cycles (Card and Moore, 1984; Raisman, 1975) is 
likely to be different between the species.
Data for losartan and PD123177 competition at hamster brain nuclei 
resembled those observed in rat brain nuclei (Rowe etai., 1992). The percentage 
of binding displaced by losartan and PD123177 at each nucleus (Table 1) 
approximates the fraction of ATt and AT2  receptors respectively. This is based 
upon assumptions that: 1) the concentration of each competitor is considerably 
higher than the IC50 for its higher affinity site and lower than the IC50 for its low 
affinity site, 2) AT1 and AT2  are the only high affinity sites for 125I-SIAII, and 
binding kinetics for the radioligand are identical at both sites. These data are not 
available for the hamster, but 125I-SIAII shows some selectivity for ATi receptors
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in the rat brain. However, since the combination of both competitors competed 
effectively for all 125I-SIAII binding in the hamster brain, and the sums of 
percentage competition for each competitor approximate 100% for most nuclei, 
we believe the values for percent inhibition for each competitor in Table 1 closely 
reflect the fractional subtype distribution. It is noteworthy that all but two nuclei 
show similar patterns of subtype predominance in both the hamster and the rat. 
The two exceptions are the medial geniculate nucleus, predominantly ATi in the 
hamster and predominantly AT2 in the rat, and the periaqueductal grey that 
contains mostly AT2 sites in the hamster and A ^  in the rat. Strikingly, there 
seems to be a fraction (approximately 21%) of specific 125I-SIAII binding sites 
uniquely within the dorsal motor nucleus of the vagus that is not displaced by 
competition with both losartan and PD123177. Further work will be required to 
determine if this is a third receptor subtype, but the existence of binding sites 
insensitive to both losartan and PD123177 has also been reported in Xenopus 
laevis oocytes (Ji etai., 1990).
Angiotensin II binding is evident in several hamster brain nuclei associated 
with cardiovascular function and several studies indicate disturbances of the 
brain angiotensin system in the spontaneously hypertensive rat. Specifically, All 
receptor binding is elevated at the subfornical organ, nucleus of the solitary tract, 
dorsal motor nucleus of the vagus, locus coeruleus, supraoptic nucleus, and the 
organum vasculosum of the lamina terminalis of the SHR (Gehlert etai., 1986b; 
Hwang et al., 1986) and we investigated the possibility of similar anomalies in a
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genetic model of hypertensive hamster (Joyner etai., 1988). W e found no 
significant 125I-SIAII binding differences in the hypertensive model as compared 
to the normotensive control strain at any of the 20 nuclei studied. Thus, the brain 
All system does not appear to be implicated in this hamster model of genetic 
hypertension.
In summary, 125I-SIAII binding in the hamster brain was localized in 
generally the same nuclei as reported for other species, and the receptor subtype 
distribution was similar to that in the rat brain. In particular, a predominance of 
ATi receptors was observed in nuclei associated with All mediated 
cardiovascular and dipsogenic functions in other species. Thus, All mediated 
central control of cardiovascular function might be operationally similar in all 
mammalian species. In some hamster brain nuclei the presence or absence of 
125I-SIAII binding is at variance with observations in other species. This occurs at 
nuclei where a role for All has not been investigated and analysis of species 
mismatches might provide clues with regard to possible All functions at these 
nuclei.
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CHAPTER 6
CHARACTERIZATION OF THE EFFECTS OF CENTRALLY ADMINISTERED  
ANGIOTENSIN II ON BRAIN CATECHOLAMINE UTILIZATION
Introduction
Angiotensin and catecholamine systems are known to interact in a number 
of ways. Peripherally, angiotensin II stimulates the release of norepinephrine 
from adrenal chromaffin cells (Marley and Bunn, 1988.), postganglionic neurons 
(Li etai., 1988), sympathetic nerve terminals in the vasculature (Wong etai., 
1992), and brown adipose tissue (Cassis and Dwoskin, 1991). Peripheral 
interaction between angiotensin and catecholamine systems reflects functional 
commonality between the two systems. Both have potent and profound 
cardiovascular actions.
Additionally, angiotensin and catecholamine systems exist within the 
brain. Anatomically, a number of brain nuclei appear to belong to both systems. 
Angiotensin immunoreactivity and angiotensin II receptors have been co­
localized with catecholamine rich cell bodies and/or nerve terminals in the locus 
coeruleus, nucleus of the solitary tract, paraventricular nucleus of the 
hypothalamus (PV), median preoptic nucleus, intermediolateral cell column and 
in the caudal and rostral ventrolateral medulla (Jenkins etai., 1995). Again, the
66
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commonality of these sites relates to cardiovascular related functions. Peripheral 
angiotensin II is known to act at the circumventricular organs to activate 
pathways involving the PV, supraoptic nucleus (SON), nucleus of the solitary 
tract, and eventually, the rostral and caudal ventrolateral medulla, to influence 
autonomic output to the peripheral cardiovascular system (Phillips, 1987; 
McKinley etai., 1990).
Central angiotensin II also acts on receptors in the PV and SON to 
stimulate release of the potent vasoconstrictor, arginine vasopressin (AVP) into 
the peripheral circulation. Additionally, angiotensin II stimulates drinking through 
complex pathways involving the subfornical organ, the anterior wall of the third 
ventricle, median preoptic nucleus, and the organum vasculosum of the lamina 
terminalis (Johnson and Edwards, 1990; Mangiapane etai., 1983). 
Catecholamines have been implicated in both of these responses (Harland etai., 
1989; reviewed in Jenkins etai., 1995). Additionally, All increases 
norepinephrine utilization in the anteroventral third ventricle of spontaneously 
hypertensive rats (Tsukashima etai., 1996). Sumners and Phillips (1983) 
demonstrated changes in norepinephrine and dopamine utilization in the 
hypothalamus, striatum and subfornical organ following intracerebroventricular 
injection of angiotensin II. Apparently, angiotensin II produces these responses, 
at least in part, by modulating catecholamine utilization in these brain regions.
More recently, central angiotensin II has been implicated in the processing 
of motor, visual, auditory, olfactory, pain, and thermal information as well as in
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cognition and learning (Barnes e ta i ,  1992; reviewed in Wright and Harding, 
1994). Three central catecholamine systems have been implicated in learning 
and memory: 1) an a-adrenergic system with neurons in the locus coeruleus 
projecting through the median forebrain bundle into the limbic forebrain (including 
amygdala), hypothalamus and neocortex; 2) a dopaminergic system with 
neurons around the interpeduncular nucleus projecting to the substantia nigra 
and through the median forebrain bundle to the hypothalamus and 
prosencephalon, and projections from the substantia nigra to the striatum; and 3) 
a (3-adrenergic inhibitory system in the basolateral amygdala (Gorelick etai.,
1975).
Angiotensin II is known to stimulate synthesis and release of 
catecholamines in the striatum and hypothalamus. Approximately 45% of all 
noradrenergic neurons in the CNS originate at the locus coeruleus (Swanson,
1976), an area known to contain angiotensin II receptors on noradrenergic 
neurcns (Rowe etai., 1990d). Angiotensin II receptors also exist on dopamine 
containing cell bodies in the substantia nigra and on their nerve terminals in the 
striatum (Jenkins etai., 1995). Angiotensin II receptors also occur in additional 
brain nuclei associated with the three catecholaminergic systems described 
above (Wright and Harding, 1994). Furthermore, dopamine antagonists block the 
cognitive effects of angiotensin II (Hyttel and Christensen, 1983). It seems likely
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that angiotensin II affects memory and learning, and may tend to act in general, 
though modulation of catecholaminergic systems.
Interestingly, there is some evidence that catecholaminergic modulation 
may be mediated, in part, through AT2 receptors (Xiong and Marshall, 1994). 
Confirmation of this finding would dramatically increase our understanding of the 
physiological role of AT2 receptors in the brain.
We hypothesize that angiotensin mediates many of its actions through 
catecholaminergic systems and that a major portion of the central catecholamine 
utilization may be influenced by central angiotensin activity. Furthermore, the AT2 
receptor may mediate a portion of this interaction.
Design and Methods 
Preliminary experiments were performed to evaluate brain dissection and 
intracerebroventricular injection methodologies and dosage and timing for a- 
methyltyrosine pretreatment. The oc-methyltyrosine pretreatment protocol was 
chosen based on the effects observed in the preliminary experiments. The 
desired effect was a 50% reduction in catecholamine levels. The rationale for this 
dosage is that catecholamine levels of 50% of normal is optimal for observing 
either increases (resulting in further depletion) or decreases (resulting in less 
depletion) in catecholamine utilization. All animals were screened with a drink 
test as described in chapter 3. Rats were pretreated with the catecholamine 
synthesis inhibitor a-methyltyrosine (200 mg/kg, IP) or saline (IP). Animals
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TABLE 6-1. CONTROL AND TREATMENT GROUPS FOR 
CHARACTERIZATION OF CENTRAL ANGIOTENSIN II EFFECTS 
ON BRAIN CATECHOLAMINE UTILIZATION.
Pretreatment (IP): Saline a-Methyltyrosine
All + All +
i.c.v. treatment: aCSF aCSF All Losartan PD123177
N: 9 10 10 10 10
treated with a-methyltyrosine were divided into four groups in a balanced design 
(table 6-1). Forty-five minutes following pretreatment, animals 
received a series of three intracerebroventricular injections as described in 
chapter 3 (figure 6-1). Intracerebroventricular injections were given at fifteen 
minute intervals and animals were decapitated fifteen minutes after the final 
injection. Brains were immediately dissected on ice into left and right cortices, 
hindbrain, forebrain and cerebellum. Brain regions were immediately 
homogenized and stored at -60°C. Catecholamines (norepinephrine, epinephrine 
and dopamine) were extracted and quantitated as described in chapter 3.
rsz;
T=0 min: saline or T=45 min: T=60 min: T=75 min: T=90 min:
a-methyltyrosine I “ I.C.V. 2nd I.C.V. 3rd I.C.V. Decapitation
pretreatment (IP) Injection Injection Injection and dissection
Figure 6-1. Time line for pretreatment and intracerebroventricular injections.
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The effect of a-methyltyrosine was determined by a Student’s t-test 
comparing saline pre-treated aCSF animals with a-methyltyrosine pre-treated 
aCSF animals. Differences between a-methyltyrosine treatment groups were 
assessed by one-way analysis of variance. Confidence levels of 0.05 and 0.01 
were used in determining significance levels in all tests.
Results
Animals surgically prepared for intracerebroventricular injections were 
screened for correct cannula placement using a test administration of angiotensin 
II (150 picomoles in 3 jil). Animals passing this drinking (table 6-2) test were 
randomly assigned to five experimental groups according to table 6-1. 
Catecholamine utilization was determined for norepinephrine, epinephrine and
TABLE 6-2. DRINKING (ML) INDUCED BY INTRACEREBROVENTRICULAR  
INJECTION OF 150 PICOMOLES OF ANGIOTENSIN II IN 3 \iL 
OF ARTIFICIAL CSF, ARRANGED ACCORDING TO 
SUBSEQUENT EXPERIMENTAL GROUPING.
saline
pretreatment
aCSF
a-methyltyrosine pretreatment
aCSF All All + Losartan All + PD123177
16.5 15.9 16.6 11.2 11.2
15.2 10.4 14.9 15.6 17.5
18.7 15.8 13.3 19.0 15.0
14.9 16.4 15.1 15.7 16.0
17.1 13.9 17.7 17.4 14.0
12.8 15.4 13.5 14.1 15.2
17.3 16.2 13.8 18.9 12.4
14.3 12.3 15.8 18.5 13.5
12.6 13.9 11.7 14.0 13.7
15.3 13.8 13.2 16.8
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Figure 6-2. Relative norepinephrine content in animals pretreated with saline (IP) and receiving 
i.c.v. injections of aCSF (saline) or a-methyltyrosine (IP) and i.c.v. injections of either aCSF, 
angiotensin II, angiotensin II + losartan, or angiotensin II + PD123177. Values fo r the saline group 
are 231 (left cortex), 227 (right cortex), 415 (hindbrain), 465 (forebrain), and 138 (cerebellum) ng 
norepinephrine per gram tissue. Error bars indicate standard deviations. ** denotes significant 
differences (p<0.01) between saline and a-methyltyrosine pre-treated animals receiving aCSF by
i.c.v. injection.
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Figure 6-3. Relative dopamine content in animals pretreated with saline (IP) and receiving i.c.v. 
injections of aCSF (saline) or a-methyltyrosine (IP) and i.c.v. injections of either aCSF, 
angiotensin II, angiotensin II + losartan, or angiotensin II + PD123177. Values for the saline group 
are 2044 (left cortex), 1679 (right cortex), 81 (hindbrain), 936 (forebrain), and 58 (cerebellum) ng 
dopamine per gram tissue. Error bars indicate standard deviations. * and ** denote significant 
differences (p<0.05 and p<0.01, respectively) between saline and a-methyltyrosine pre-treated
animals receiving aCSF by i.c.v. injection.
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Figure 6-4. Relative epinephrine content in animals pretreated with saline (IP) and receiving i.c.v.
injections of aCSF (saline) o r a-methyltyrosine (IP) and i.c.v. injections of either aCSF, 
angiotensin II, angiotensin II + losartan, or angiotensin II + PD123177. Values for the saline group 
are 5.9 (hindbrain) and 5.5 (forebrain) ng epinephrine per gram tissue. Error bars indicate 
standard deviations. * denotes significant differences (p<0.05) between saline and a- 
methyltyrosine pre-treated animals receiving aCSF by i.c.v. injection.
dopamine in the presence and absence of the catecholamine synthesis inhibitor 
a-methyltyrosine (figures 6-2 - 6-4). Catecholamine levels are adjusted for wet 
tissue weight and expressed as a percentage of saline pretreated levels to 
facilitate comparisons. All brain regions demonstrated a highly significant 
(p<0.01) decrease (24 ± 3% ) in norepinephrine levels in animals pretreated with 
a-methyltyrosine (figure 6-2). Similarly, dopamine levels (figure 6-3) in a- 
methyltyrosine animals were 63 ±  6% of saline pretreated animals (significant in 
four of the five brain regions). Epinephrine levels were detectable in only the 
hindbrain and forebrain (figure 6-4) and demonstrated a significant
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a*methyltyrosine effect in only the forebrain. Unexpectedly, there were no 
significant differences observed between a-methyltyrosine treated animals 
receiving intracerebroventricular injections of aCSF, All, or All in addition to 
either subtype selective antagonist. This was true for all three catecholamines 
observed in all five brain regions.
Discussion
Our methods were sufficiently sensitive to detect 15% changes in 
catecholamine content following treatment with a-methyltyrosine. The finding of 
no angiotensin II effects implies that despite the extensive anatomical and 
functional overlap between the central angiotensinergic and catecholaminergic 
systems, the portion of the catecholaminergic system that is influenced by 
intracerebroventricularly administered All represents a small fraction of the total 
central catecholamine content.
This unexpected finding is difficult to explain considering reports based on 
alternative experimental designs employed by other laboratories. Sumners and 
Phillips (1983) demonstrated significant alterations in catecholamine utilization in 
the hypothalamus and striatum micropunches following intracerebroventricular 
angiotensin II administration. These finding have been corroborated by Stadler et 
al. (1992) and Mendelsohn etai. (1993). Furthermore, the catecholaminergic 
actions of angiotensin II appear to be more pronounced in spontaneously 
hypertensive rats (Tsukashima etai., 1996). Recent reports indicate that
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angiotensin II regulates tyrosine hydroxylase gene expression (Yu etai., 1996) 
and norepinephrine transport system (Lu e ta i,  1996) in neuronal cultures of both 
normotensive and spontaneously hypertensive rats.
There is some evidence that angiotensin II modulates the responsiveness 
of catecholamine containing neurons to other stimuli. Xiong and Marshall (1990; 
1994) have demonstrated that All modulates the response of locus coeruleus 
neurons to glutamate excitation via an AT2 receptor mediated pathway. Similarly, 
angiotensin II potentiates potassium induced norepinephrine (Qadri etai., 1991) 
and dopamine (Badoer etai., 1990) release in the hypothalamus. Furthermore, in 
the periphery, angiotensin II facilitated adrenal catecholamine release in 
response to splanchnic nerve stimulation in hemorrhaged dogs (Kimura etai., 
19S2). However, angiotensin II probably activates catecholaminergic neurons in 
a direct manner through a pathway that is synergistic to those of alternative 
stimuli.
Nevertheless, even a less direct role for angiotensin II in regulating 
catecholamine utilization would fail to completely explain our results. However, 
additional angiotensin II activity and/or secondary effects of i.c.v. injection may 
have interfered with our measurements. We occasionally observed slight motor 
effects and some catatonia following i.c.v. injections, with subsequent detrimental 
effects on drinking responses for All treatment groups. These effects occurred 
without regard to treatment group and the few affected animals did not
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demonstrate aberrant characteristics with regard to unaffected drinking 
responses. Furthermore, the All treatment group demonstrated no correlation 
between catecholamine response and volume drank (NE correlation depicted in 
figure 6-5) nor time until onset of drinking (not shown). Therefore, the inclusion or 
exclusion of these animals does not significantly alter our findings. However, 
these observances indicate the potential existence of similar effects that may be 
less observable and more frequent, but that may be equally or more detrimental 
with respect to catecholamine responses. These effects probably involve 
pathways and brain areas adjacent to the target injection site that are 
inconsistently affected depending on the exact cannula placement.
Additionally, we cannot rule out the possibility that angiotensin II acts 
directly on catecholaminergic neurons in only a few very discrete anatomical
§  « s o  o
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Figure 6-5. Correlation of norepinephrine and drinking responses following 
intracerebroventricular administration of angiotensin II.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
77
locations. In our preparation, such responses may be masked by the background 
changes in catecholamine content throughout the remainder of the brain. It is 
also possible that angiotensin II alters catecholamine utilization differently in 
different brain nuclei. The interaction of ATt and AT2 receptors may also differ in 
different brain areas.
The experimental design was chosen to obtain a summation (within brain 
regions) of potentially small individual catecholamine responses for ATt and AT2 
receptors. Our results indicate that the nature of the interaction between the 
central angiotensin II and catecholaminergic systems makes this approach 
inappropriate. Because we failed to detect a significant angiotensin II effect, the 
use of subtype selective antagonists failed to provide additional information.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 7
SUMMARY, CONCLUSIONS, AND PERSPECTIVES
Nearly a century has been invested in studying the renin-angiotensin 
system. Many rewards are already apparent. Inhibition of the peripheral renin- 
angiotensin system has proven very effective in the management of some forms 
of hypertension. The discovery of angiotensin II receptor subtypes and the 
availability of selective antagonists will likely provide these benefits with little or 
no side effects.
The discovery of a separate angiotensin system in the brain may lead to 
additional clinical advances. In addition to cardiovascular regulation, the central 
angiotensin system has been implicated in the processing of many types of 
sensory information, and in memory and cognition. And we continue to discover 
additional functions of this system. These findings suggest that this system may 
offer insight into certain dementia including Alzheimer’s disease.
The diverse activity of the angiotensinergic system is possible because of 
the diversity of angiotensin receptor subtypes and active peptides. Angiotensin- 
(1-7) and angiotensin IV appear to act through a unique receptor subtypes 
(Ambuhl etai., 1994; Swanson etai., 1992) and there are two types of 
angiotensin II receptors (ATi and AT2). Further characterization of these 
receptors and isolation of the subtypes will allow the many actions of this
78
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system to be studied independently. The utilization of modem tools of molecular 
biology are already providing insight into these receptor populations (Nahmias 
and Strosberg, 1995) and angiotensin peptides (Lynch and Peach, 1991).
Our research demonstrates the significance of in vitro conditions and 
underscores the need to validate in vitro procedures and to be aware of 
assumptions implicit in these procedures. We have validated the binding assay 
employed in our laboratory and demonstrated subtype selective effects for some 
commonly used buffer constituents. W e also ascertained the degree of 
degradation in the absence and presence of individual peptidase inhibitors for 
our substituted radioligand. W e then utilized this system in two approaches to 
characterize further the functional role of central angiotensin II.
We compared the anatomical distributions of normal hamsters, genetically 
hypertensive hamsters and the previously determined distribution in the rat. 
Identification of sites differing in angiotensin II receptor content and subtype 
composition (inferior olive, suprachiasmatic nucleus, medial amygdala, piriform 
cortex, subthalamic nucleus, anterior pituitary, hippocampus, striatum, 
dorsomotor nucleus of the vagus, medial habenula, and the interpeduncular 
nucleus) may direct more focused investigations. These differences may 
correlate to physiological differences between the two species.
Unlike genetically hypertensive and normotensive rats, hamsters did not 
demonstrate elevated levels of angiotensin II receptors in the brains of 
hypertensive animals. This finding illustrates the complexity of hypertension
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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pathology and indicates that the hamster model may (in some cases) provide an 
alternative model to the spontaneously hypertensive rat. The differences 
between these models probably relate to different mechanisms of hypertension.
We also investigated the interaction between angiotensin and 
catecholamine systems within the brain. Our intent was to demonstrate extensive 
general interaction between the two systems and confirm a role for the AT2 
receptor subtype in this interaction. Our findings suggest that interactions 
between these systems are more complex and less homogenous than we 
anticipated. Additional work is necessary to determine the nature of these 
interactions.
Even though we were unable to answer all of our questions, we have 
uncovered some of the complexity of the central angiotensin system. Now, we 
must ‘zoom in’ and isolate specific characteristics for more direct examination. 
The species differences in receptor binding include many brain nuclei at which 
the function of angiotensin II is not presently known. Additional work may 
associate these differences with known physiological differences between the 
animal models. Much work needs to be done to examine the potential 
neuromodulatory role for angiotensin II in catecholaminergic systems. The exact 
role each of these systems and their interaction in memory formation and 
cognition remains to be determined. Perseverance and continuing advances in 
technology will eventually resolve these challenges.
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